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CHAPTER I 
INTRODUCTION AND LITERATURE REVIEW 
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Thoracic Aortic Aneurysms and Dissections 
 An aneurysm is an enlargement or dilatation of an artery, and a dissection is a tear 
partway through the aortic wall, creating a false lumen for blood flow. Aortic aneurysms and 
dissections are the most common type of aortic disease and are a leading cause of death in 
the U.S., affecting approximately 6 out of every 100,000 people and claiming approximately 
16,000 lives each year (1;2). Aneurysms of the ascending aorta are defined as greater than or 
equal to 1.5 times the size of the normal aorta (3). Aneurysms can occur anywhere along the 
length of the aorta and are classified according to anatomical location. Thoracic aortic 
aneurysms account for approximately 48% of all aneurysms (2). The natural progression of 
aneurysms is to progressively enlarge over time until the vessel wall weakens and eventually 
dissects. An aortic dissection can either be acute (diagnosed less than 2 weeks after the 
dissection occurred) or chronic, and can occur as part of a spectrum of aortic disease even 
without aneurysm formation (4). Dissections are most commonly classified using either the 
Stanford system or the DeBakey system. According to the Stanford classification, Type A 
dissections involve the ascending aorta, and may also involve the arch or descending aorta, 
while Type B dissections involve only the descending aorta. According to the DeBakey 
system, dissections are classified as Type I, Type II, or Type III. A Type I dissection 
involves the entire length of the aorta, a Type II dissection includes only the ascending aorta, 
and a Type III dissection includes only the descending aorta (5).  
 Aneurysms are generally asymptomatic until a catastrophic event i.e. a dissection 
occurs. Some patients develop chronic heart failure as the aneurysm expands due to 
distortion of the aortic valve and subsequent aortic valve insufficiency, but aneurysms 
remain largely undetected until they either dissect or rupture (5). Symptoms of an aortic 
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dissection, including sudden and severe chest pain, are similar to those of a myocardial 
infarction and are initially misdiagnosed in up to 30% of cases, and this misdiagnosis can 
prove to be deadly (5-7). Beta-adrenergic receptor blocking agents are currently used to 
lower blood pressure in patients (8;9). However, while these drugs can slow the rate of 
aneurysm growth, they do not prevent aortic disease from eventually progressing to 
dissection (10). No drug treatment to prevent the underlying disease process exists. The only 
available treatment option when the aorta continues to enlarge despite beta-blocker therapy 
is surgical repair of the aorta once an aneurysm reaches a certain size or growth rate (5). A 
dissection must be emergently repaired in order to prevent death, since the mortality rate 
increases by 1% to 2% every hour after an acute dissection (9). Recommendations for 
treatment are based on the size of the aneurysm, its location, and its rate of growth. 
Individuals are generally referred for surgery when the aneurysm reaches a diameter of 5.5-
6.0 cm for patients, or if the aneurysm grows more than 0.5 cm in 6 months as assessed by 
serial MRI scans. For patients with a family history, surgery is recommended once the 
aneurysm reaches a diameter between 4.5-5.0 cm. Surgical repair involves replacing the 
aneurysmal portion of the aorta with a Dacron graft (5).  
 The aortic wall is composed of three major layers: the intima, media, and adventitia. 
The intima is composed of one layer of endothelial cells. Although the endothelial layer in 
small arteries is responsive to shear stress and is involved in regulation of vascular tone, it is 
not clear whether the endothelium of large arteries, including the aorta, is involved in this 
type of regulation. The medial layer is composed of smooth muscle cells and elastic fibers. 
Elastic fibers are composed of elastin as well as fibulin and fibrillin-containing microfibrils, 
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and enable the aorta to return to a normal size and shape after stretching due to pulsatile 
blood flow (Figure I-1) (11).  
 
Figure I-1. Aortic wall structure. H&E and Movat staining of control (A,C) and aneurysmal 
(B,D) aortic tissue, showing the three major layers of the aortic wall. Tissues are oriented 
with the adventitial layer at the top of the image. In the Movat stains, elastic fibers are black, 
cells are red, proteoglycans are blue, and collagens are yellow. In normal aortas (A,C), the 
outer adventitial layer contains small blood vessels that supply nutrients to the aortic wall, a 
e 
f 
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medial layer composed of elastic fibers (black) and SMCs (red), and an intimal layer 
composed of endothelial cells. SMCs and elastic fibers are arranged in concentric layers (E) 
and are interconnected with contractile filaments in SMCs through focal adhesions (E,F). In 
contrast, aneurysmal aortas (B,D) are characterized by areas of proteoglycan accumulation 
(blue) and focal areas of SMCs loss. Adapted from (12).  
************************************************************************** 
Fibrillin-1 has both a structural role and a regulatory role within the vessel wall. 
Fibrillin-1 binds to αvβ3, α5β1, and αvβ6 integrins on the surface of SMCs, contributing to 
aortic wall structure (13). Additionally, fibrillin contains multiple latent TGF-β binding 
protein (LTBP) domains and a specific fragment of fibrillin-1 is capable of releasing TGF-
β1 from large latent complexes in the ECM, leading to TGF-β1 activation (Figure I-2) (14).  
 
Figure I-2. Fibrillin-1 controls TGF-β1 activation. Fibrillin-1 has structural similarities to 
and associates with large latent complexes containing LTBP-1, latency-associated peptide 
(LAP), and TGF-β1. The small latent complex (SLC) is composed of TGF- β1 and LAP. 
Breakdown in the structure of fibrillin-1 can lead to TGF- β1 activation through cleavage of 
the latent complex and release of TGF-β1 peptide into the extracellular matrix. Adapted by 
permission from Macmillan Publishers Ltd: [Nature Genetics] (15), copyright (2003). 
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**************************************************************************
Fibulin-4 and fibulin-5 play an essential role in assembly of elastic fibers within the vessel 
wall, and loss of either of these proteins results in severe vascular defects (16;17). Elastin 
deficiency in mice and humans results in excessive SMC proliferation and the development 
of supravalvular aortic stenosis (SVAS), highlighting the importance of elastin in both 
maintaining the structural integrity of the aorta and in maintaining SMCs in a quiescent, 
contractile state (18). Elastic fibers and SMCs are arranged in concentric layers within the 
aortic wall, with each layer of SMCs and its associated elastic fibers representing one 
lamellar unit (Figure I-1E) (11).  
The third major layer of the aorta is an outer adventitial layer containing 
myofibroblasts, adipose tissue, small nerve endings, and vasa vasorum, small blood vessels 
located close to the medial surface that supply nutrients to the vessel wall. Aneurysms are 
characterized by medial degeneration, including loss and fragmentation of elastic fibers, 
SMC loss, proteoglycan accumulation, and in some cases are accompanied by inflammation 
(Figure I-1B,D) (19-21). Proteoglycan accumulation is one of the earliest pathologic 
findings and has been found prior to aneurysm formation (22). Fragmentation of elastic 
fibers is the most common feature and is found in >90% of aneurysms, while cystic medial 
changes, SMC loss, atherosclerotic changes, and thickening of the vasa vasorum were found 
in 70%, 45%, 41%, and 20% of ascending aneurysms (19). Numerous studies have shown 
increased expression of multiple matrix metalloproteases (MMPs), which cause ECM 
degradation and account for some of the pathologic changes observed in TAAD, particularly 
elastic fiber degradation (23-25). These processes lead to weakening of the aortic wall, 
leaving it more prone to dissect.   
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 In 1991, missense mutations in FBN1, encoding fibrillin-1, were found to cause 
Marfan syndrome (MFS, OMIM no. 154700) (26). MFS is inherited in an autosomal 
dominant manner, occurs in approximately 1 out of every 5,000 individuals, and leads to 
TAAD as well as a number of pleiotropic effects including mitral valve prolapse, long bone 
overgrowth, joint hypermobility, and ectopia lentis (27). FBN1 mutations result in altered 
secretion and deposition of fibrillin-1 in the ECM (28). These studies provided the first 
evidence that aortic aneurysms could be caused due to a single gene defect.  
Approximately 20% of individuals with TAAD have one or more affected family 
members, providing evidence of a genetic basis for nonsyndromic TAAD (29;30). 
Aneurysms are inherited in these families in an autosomal dominant manner, and exhibit 
variable ages of onset and decreased penetrance (4). In addition, these families show 
variability in the associated cardiovascular complications associated with the thoracic aortic 
disease, including bicuspid aortic valve, intracranial aneurysms and popliteal aneurysms (3).  
So far, seven published loci have been linked to TAAD, and the putative genes at four of 
these loci have been identified (20;31-34). Several additional mutations and/or loci have 
been identified and are currently being further confirmed and characterized.  
Mutations in TGFBR1 and TGFBR2, encoding for the transforming growth factor-β 
type I and II receptors, respectively, have been identified as causes of familial TAAD 
(32;35). These findings, along with studies of TGF-β1 signaling in other aneurysm 
syndromes associated with TGFBR1 or TGFBR2 mutations, led to the hypothesis that 
familial TAAD may be driven, at least in part, by dysregulation of TGF-β signaling (3). 
However, mutations in TGFBR1 or TGFBR2 account for less than 5% of familial TAAD. 
Furthermore, dysregulation of TGF-β signaling as a common mechanism driving TAAD is 
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controversial. More recently, mutations in ACTA2 and MYH11 encoding for the smooth 
muscle cell (SMC)-specific contractile proteins SM α-actin and myosin heavy chain (SM-
MHC), were found to cause TAAD (34;36). While MYH11 mutations account for <2% of 
familial TAAD cases, ACTA2 mutations account for approximately 15% of familial TAAD 
cases, making contractile gene mutations the most common cause of familial TAAD 
(34;36). Subsequently, mutations in MLCK, encoding myosin light chain kinase, were 
identified as a cause of familial TAAD (Wang et al, manuscript submitted).  
 Approximately 80% of TAAD cases occur in individuals with no known family 
history of aortic disease. Sporadic aneurysms generally have a later age of onset than 
familial aneurysms (30). The major causes remain unknown; however, the pathology 
associated with the TAAD cases is highly similar. Regardless of the major causes of 
sporadic TAAD, much insight can be gained from study of the pathogenesis of familial 
TAAD and potentially applied to aid in management of sporadic patients also.  
 In addition to MFS and nonsyndromic familial TAAD, multiple genetically inherited 
syndromes are associated with this spectrum of disease. Part of this spectrum of diseases 
includes defined syndromes as well as nonsyndromic familial TAAD due to mutations in the 
TGF-β receptors. Furlong et al. described a Marfan-like syndrome in 1987 characterized by 
craniosynostosis and TAAD; however, the genetic mutation was not identified (37). Loeys-
Dietz syndrome was characterized in 2005, was found to share similar characteristics with 
Furlong syndrome, and was found to be caused by mutations in either the TGF-β type I or II 
receptors (38). Subsequently, patients with the originally diagnosed Furlong syndrome were 
also found to harbor TGFBR2 mutations (39). Mutations in these receptors also lead to 
familial TAAD. In this subgroup of patients, major features of Loeys-Dietz syndrome are 
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missing but aneurysms also present in arteries other than the aorta, particularly in patients 
with TGFBR1 mutations (35).  
 Some degree of overlap exists in the aneurysm disease phenotypes caused by these 
mutations. For example, TGFBR2 mutations have been shown to lead to multiple distinct 
aneurysm disorders, including LDS, familial TAAD, and MFS (32;38;40). Unique features 
found in LDS but not MFS or one other closely related syndrome include arterial tortuosity, 
cleft palate, atrial septal defects, and patent ductus arteriosus; however, a patient with 
Furlong/LDS was found to harbor an FBN1 mutation (38;39). Additionally, TGFBR2 
mutations were found in a subset of patients with clinical features of Marfan syndrome (40). 
An ongoing controversy exists over whether TGFBR2 in addition to FBN1 mutations result 
in true cases of MFS (41). A more recent study of 547 probands showed that TGFBR1 and 
TGFBR2 mutations cause LDS in 87.5% of cases, but also cause MFS or familial TAAD in 
the remainder of the cases (42). The majority of the data indicate that these disorders 
represent a spectrum of disease caused by multiple different mutations, rather than single, 
isolated clinical entities. The presence of these overlaps in phenotype could have 
implications for the clinical management of disease.  
Vascular Ehlers-Danlos syndrome (EDS) represents another inherited genetic 
syndrome associated with aneurysms, and is caused by mutations in the COL3A1 gene, 
encoding type III procollagen (43). Individuals with vascular EDS have aneurysms, 
dissections, and rupture of various arteries throughout the body but can also develop TAAD.  
In addition, these individuals have thin, translucent skin, atrophic scars, and are predisposed 
to bowel rupture, along with rupture of the gravid uterus. Repair of ascending aneurysms in 
these individuals is difficult due to the fragility of the vessel tissue (43). Other disorders that 
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also lead to TAAD in more rare cases include EDS associated with filamin A mutations, 
tuberous sclerosis caused by TSC2 mutations, Turner syndrome, osteogenesis imperfecta, 
Alagille syndrome, and adult polycystic kidney disease (44-48).  
 Additional factors contributing to the development of TAAD include genetic 
polymorphisms and environmental risk factors. A polymorphism in the MMP9 gene is 
associated with TAAD (49). Hypertension and environmental factors, including 
weightlifting, can also both induce aneurysm formation and aggravate aneurysm phenotypes 
in individuals who are already genetically predisposed to TAAD (12).  
 In summary, TAAD represents a spectrum of disease exhibiting both genetic and 
phenotypic heterogeneity, as well as overlap among some of the specific defined syndromes. 
Although much has been done to advance the field in terms of improving surgical 
techniques and outcomes and identifying novel mutations leading to disease, the precise 
mechanisms leading to medial degeneration and expansion of the vessel wall are still not 
completely understood, and viable non-surgical treatment options for this spectrum of 
disease are lacking.   
 
SMC Biology and Blood Vessel Biology 
 An understanding of the structure and function of SMCs and arteries is essential for 
gaining insight into the pathogenesis of TAAD. Vascular SMCs arise from multiple different 
origins during development, and a summary of these origins is shown in Figure I-3.  
11 
 
Figure I-3. Diverse developmental origins of vascular SMCs. Vascular SMCs arise from 
multiple embryonic origins, and are color coded accordingly. Reprinted by permission from 
Wolters Kluwer Health (50), copyright (2007).  
**************************************************************************
For example, SMCs in the ascending aorta as well as the carotid arteries arise from neural 
crest cells, while SMCs in the descending aorta are mesenchymal derived (50). Treatment of 
neural crest derived vs. mesenchymal derived cells with TGF-β1 results in different cellular 
responses, suggesting that these cells are functionally similar but not completely identical 
(51).  
 In contrast to skeletal and cardiac myocytes, which are terminally differentiated, 
SMCs are able to switch between a quiescent, contractile phenotype and a proliferative, 
synthetic phenotype (52;53). SMC phenotypic plasticity is closely tied with contractile 
function and response to external stimuli including stretch (54). Differentiated SMCs are 
generally quiescent and non-proliferative, and are characterized by prominent stress fibers 
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and high expression of contractile proteins including SM α-actin, smooth muscle β-myosin, 
calponin, smoothelin, SM22, and tropomyosins (54;55). Dedifferentiated SMCs have a more 
synthetic phenotype characterized by increased amounts of rough endoplasmic reticulum 
and large Golgi complexes, decreased contractile protein expression, more production of 
ECM proteins, and increased proliferation and migration (55). These two phenotypes are not 
necessarily mutually exclusive of one another, however (56).  
 Phenotypic switching to a more de-differentiated state allows SMCs to repair the 
vessel wall after injury. However, in disease states an overabundance of this response proves 
to be detrimental (54). SMC phenotypic modulation plays an important role in vascular 
proliferative diseases including atherosclerosis and restenosis of vascular stent grafts (57). 
Dedifferentiated SMCs are also found in aneurysms (22). Regulation of SMC phenotype is 
highly complex, is mediated by a variety of extracellular signals, and is transcriptionally 
regulated through multiple different pathways. Serum response factor (SRF) acts as a 
molecular switch, regulating either a contractile phenotype or a proliferative phenotype, 
dependent on its binding to either the myocardin family of transcription factors to promote 
SMC gene expression, or ternary complex factors (TCFs), to promote expression of 
proliferative genes (58). Multiple cytokines and growth factors also contribute to SMC 
phenotypic modulation. PDGF-β is known to potent stimulator of SMC proliferation and 
migration, while TGF-β1 has been known to promote either differentiation or proliferation 
depending on the concentration used (51;54).  
 The proper contractile function of differentiated SMCs is essential for maintaining 
structural integrity within the vascular wall. SMCs differ from cardiac and skeletal muscle in 
that they lack sarcomeres, but the sliding filament mechanism of contraction in SMCs is 
13 
similar to the mechanism in striated muscle cells, and provides a means of generating 
contractile force (59;60). Multiple proteins are involved in the regulation of SMC actin-
myosin crossbridge cycling, including tropomyosin, calponin, and caldesmon: actin and 
myosin are the major focus of this study.  Myosin consists of two heavy chains, two 
essential light chains, and two regulatory light chains. Each myosin heavy chain is 
composed of a globular head domain that has ATPase activity, and an α-helical coiled-coil 
region (61). ATP exchange causes release of myosin from actin filaments, along with a 
conformational change in the myosin head domain (Figure I-4A,B).  
 
Figure I-4. Myosin crossbridge cycling. ATP exchange and hydrolysis results in a “power 
stroke” that results in shortening of actin and myosin filaments and subsequent muscle 
contraction. From (62). Reprinted by permission from AAAS.  
**************************************************************************
Binding of actin to myosin accelerates the rate of ATP hydrolysis. Subsequent release of the 
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phosphate causes in another conformational change in myosin, pulling on the filaments and 
resulting in muscle shortening (Figure I-4C-E) (61).  
 In contrast to the structure of skeletal and cardiac myocytes, where filaments are 
bundled together in a distinct pattern into myofibrils, contractile filaments in SMCs are 
distributed in a nonuniform manner, and can adapt their length and organization in response 
to stimuli (60;63). Additionally, SMCs are thought to bundle and act together in a 
mechanical syncytium rather than as single cells contracting individually, allowing for force 
to be distributed uniformly among the cells (60). In this model, contractile filaments are 
attached to the cell membrane at dense plaques, which are structures homologous to the 
focal adhesions (FA) observed in other cell types (60;64). FAs form a critical link between 
the ECM and contractile elements in the cell, creating a continuum along which mechanical 
force signals can be transduced, and also regulate intracellular signaling (65;66). Focal 
adhesion kinase (FAK) is a critical part of the FA complex, acting as a mechanosensor, a 
scaffold for recruitment of other proteins to these complexes, and a regulator of FA turnover 
(67;68). In FAK-deficient SMCs, Ca2+ signaling and cellular contractility in response to 
acetylcholine and KCl are disrupted, demonstrating the importance of intact FAK activation 
for proper SMC contractile function (69). Overall, FAs play an essential role in both 
regulating tension development and SMC contractility and mediating cell signaling events; 
however, specific roles of FAs in TAAD pathogenesis have not yet been described.   
  As stated previously, SMCs are arranged in concentric layers between elastic 
lamellae in the aortic wall (70). Large arteries have a high elastin content and are able to 
withstand higher pressures from blood flow than smaller arteries. The high elastin content 
promotes a differentiated SMC phenotype, and has an inhibitory effect on SMC proliferation 
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(57). In contrast, smaller arteries are subjected to less pressure from blood flow and are more 
muscular in structure, containing an internal and external elastic lamina, but no elastic 
lamellae. Small arteries are also prone to excessive SMC dedifferentiation, proliferation, and 
migration in response to injury. Numerous studies have shown that carotid artery injury 
causes SMC proliferation and migration, leading to formation of a neointimal layer of SMCs 
and ultimately to vessel occlusion (71-73).  
 
Current Understanding of TAAD Pathogenesis 
 Multiple diverse pathways contribute to TAAD pathogenesis, and some insight has 
been gained both from the study of TAAD as well as abdominal aortic aneurysms. Some of 
the major pathways and processes identified include TGF-β1 signaling, SMC phenotypic 
switching, increased MMP expression, and more recently, SMC contractile dysfunction.  
 Most of the current TAAD research is focused on the role of TGF-β signaling in the 
disease process. This is partly owing to the fact that the Fbn1 underexpressing and Fbn1 
mutant mice were the first mouse models developed to understand the pathogenesis of MFS, 
and more broadly, TAAD. These models have suggested a role for TGF-β signaling in 
aneurysm formation in Marfan syndrome (10). Increased phospho-Smad2, an indicator of 
TGF-β1 signaling, was found in aortas of patients with LDS (38). This increase is 
paradoxical because the mutations in TGFBR1 and TGFBR2 are all located in the 
intracellular kinase domain and are predicted to result in decreased kinase function, thereby 
disrupting TGF-β signaling (38). Losartan, an angiotensin II receptor antagonist, prevents 
Smad2 phosphorylation, medial degeneration, and aneurysm formation in the MFS mouse 
model (10). Clinical trials are underway to determine whether Losartan delays disease 
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progression in individuals with MFS (74). However, no established treatment currently 
exists for directly delaying and/or preventing aneurysm formation either in individuals with 
MFS, or with other syndromic or nonsyndromic conditions that predispose to aneurysm 
formation.  
Some controversy exists as to whether TGF-β1 signaling represents a common 
pathway leading to familial TAAD. SMCs from familial TAAD patients without identified 
mutations show a common dysregulation of stretch-induced signaling pathways (Lafont et 
al, manuscript submitted). Mutations leading to TAAD have been identified in genes that 
regulate contractility, ECM genes, and specific contractile genes, which are all part of the 
SMC-integrin-ECM continuum. Additionally, all existing mutations leading to TAAD can 
be linked, directly or indirectly, to some component of this axis (12).  
 SMC phenotypic switching is also likely to play an important role in the disease 
process. In an elastase perfusion model of abdominal aneurysms, phenotypic switching 
occurred, characterized by decreased levels of SM α-actin and SM22α and increased 
expression of MMP2 and MMP9, and preceded aneurysm formation (75). Other studies 
have shown that expression of proteoglycans and matrix metalloproteases (MMPs) are 
upregulated in the vessel wall, consistent with a more synthetic SMC phenotype. A mouse 
model of MFS harboring a heterozygous mutation for Fbn1 displayed increased expression 
of MMP2 and MMP9 along with decreased overall aortic contractility and increased 
degradation of elastic fibers (24). Treatment of MFS mice with doxycycline, a nonspecific 
MMP inhibitor, prevented medial degeneration, aneurysm formation, and aortic rupture 
(76;77). One of the earliest histologic findings in medial degeneration is proteoglycan 
accumulation within the aortic wall (22). Data from our lab indicate that this accumulation 
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occurs at least in part through the induction of stretch-induced signaling pathways (Lafont et 
al., manuscript submitted). Inflammation, angiotensin II signaling, and oxidative stress 
represent other factors involved in the development of TAAD (21;78;79). Additionally, 
SMC loss and/or SMC proliferation play a role in TAAD pathogenesis. Some debate exists, 
however, over whether SMC loss, SMC proliferation, or a combination of both occurs in 
aneurysms (80-82). Upon pathologic examination of aneurysmal aortic tissues, focal areas of 
SMC loss within the tissue are a clear and common finding. However, some studies have 
reported increased overall medial area combined with no change in SMC density in TAA, 
suggesting an increase rather than a decrease in SMCs (82). It is possible that an early 
proliferation is present, followed by later apoptosis and loss of SMCs. However, the specific 
contribution of cell proliferation to TAA formation is currently not known.  
A growing body of evidence strongly suggests that SMC contractile dysfunction is 
one of the primary underlying defects leading to aneurysm formation, but the specific 
mechanisms by which SMC-specific contractile gene mutations cause contractile 
dysfunction and aneurysm formation are not yet known. Also, vascular disease in 
individuals heterozygous for contractile mutations is not confined just to the aorta. ACTA2 
and MYH11 mutations lead to development of early onset coronary artery disease and 
stroke, in addition to TAAD. The segregation of additional vascular diseases in individuals 
heterozygous for these mutations represents a novel disease phenotype (83). A conclusive 
explanation of how aneurysms and occlusive diseases are caused by a single missense 
mutation is lacking. Investigation into the mechanisms leading to disease in these 
individuals should provide vital information about aneurysm formation, and may also 
provide insight into pathogenesis of these additional major cardiovascular diseases. Our 
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overall hypothesis for this study is that that SMC-specific contractile gene mutations lead to 
both aneurysms and occlusive diseases through disruption of contractile filaments and loss 
of SMC contractility, coupled with a gain of  function effect of the mutation, leading to 
increased SMC proliferation.  
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CHAPTER II 
CHARACTERIZATION OF THE VASCULAR AND CELLULAR PHENOTYPE IN 
TAAD PATIENTS HETEROZYGOUS FOR MYH11 MUTATIONS 
20 
Background 
 A study reported inheritance of thoracic aortic aneurysms/dissections associated with 
PDA in a single small family (84). Patent ductus arteriosus (PDA) results from a failure of 
the ductus arteriosus, the fetal blood vessel connecting the pulmonary artery to the aortic 
arch, to close properly at birth.  Subsequently, Van Kien et al described familial TAAD 
accompanied by PDA in a large French family (85). The disease in this family was not 
associated with any other known locus for TAAD, or any other known locus for PDA. The 
disorder was hypothesized to occur due to a single gene defect (85).  This hypothesis was 
confirmed when the disease in the French family was mapped to a single locus on 
chromosome 16p12.2-p13.13 using a genome-wide scan followed by fine mapping of the 
locus using microsatellite markers (86). In 2006, MYH11 was identified as the disease-
causing gene at this locus through sequencing in the critical interval on chromosome 16p 
(33). A heterozygous missense mutation and a splice-site mutation leading to deletion of 
exon 32 were identified in the French family, and a 72-base pair deletion in exon 28 was 
identified in the American family, whose TAAD/PDA had been previously reported in 2001. 
The mutations in both kindred were predicted to affect the coiled-coil structure of myosin, 
disrupting assembly of myosin filaments within the cell (33). Subsequently, our lab 
identified unique MYH11 missense mutations in two unrelated families with the combined 
phenotype of TAAD and PDA (36). In the first family, an R712Q mutation was found in the 
ATPase head domain of myosin and was predicted to disrupt the ATPase activity. Two 
closely linked missense mutations, at R1275L and L1264P, were identified in the second 
family. Both residues are located on the coiled-coil domain of myosin, but only L1264P was 
predicted to disrupt coiled-coil formation (36). 
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 MYH11 is the second gene to be associated directly with non-syndromic familial 
TAAD. Although MYH11 mutations are relatively rare, they represent the first TAAD 
mutations found in a SMC-specific contractile gene, and study of the cellular effects of these 
mutations should yield important information about TAAD pathogenesis. All of the families 
assessed both by Zhu et al. and Pannu et al. displayed an inheritance pattern similar to 
TAAD caused by other mutations, including variable age of onset and decreased penetrance 
(33;36). Individuals with MYH11 mutations were found to have increased aortic stiffness 
due to decreased compliance and distensibility prior to demonstrating aortic enlargement 
(86). Aortas of patients heterozygous for MYH11 mutations showed typical features of 
medial degeneration, including fragmentation and loss of elastic fibers, areas of SMC loss, 
and accumulation of proteoglycans (33). Both the wildtype and mutant protein were 
expressed in equal amounts in the aortic wall; however, MYH11 in the mutant aortic tissue 
was found to be less stable. Normal immunostaining of MYH11 was observed in frozen 
aortic tissue from patients compared with controls, but MYH11 staining was absent in 
formalin-fixed tissues from patients, suggesting that the MYH11 mutations render the 
protein more susceptible to denaturing by formalin fixation. Additionally, labeled mutant 
and wildtype constructs containing the rod domain failed to co-localized when both were 
expressed in Rb-1 cells (rabbit SMCs). Based on these data, the authors suggested that the 
mutant protein behaved in a dominant-negative manner (33).  
 Eight myosin heavy chain isoforms are expressed in muscle tissue, and multiple 
other isoforms exist as well (87). SM-MHC is an essential component of the SMC 
contractile apparatus, as shown by studies of knockout mice. SM-MHC knockout mice do 
not survive more than 72 hours after birth. These mice appear to be starved, and display a 
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failure of proper bladder emptying, along with delayed closure of the ductus arteriosus, 
demonstrating the importance of this protein for proper SMC contractile function (88). 
Mutations in other myosin heavy chain isoforms also emphasize the indispensability of this 
protein in muscle contraction, and provide supporting evidence that MYH11 mutations have 
deleterious effects on SMCs. Mutations in MYH7 cause hypertrophic cardiomyopathy (89). 
Structural analysis of the MYH11 mutations showed that the R712Q mutation present in one 
family is heterologous to the R705 mutations in MYH9 that lead to hereditary deafness (36). 
The mutation in this nonmuscle myosin (myosin IIA) results in decreased stability of the 
protein structure, and reduced ability of the mutant myosin to couple ATPase activity with 
cell movement, resulting in decreased cell motility (90;91). Therefore, the mutation at R712 
in MYH11 is likely to also disrupt function of myosin within the cell.  
 Little is currently known about the specific pathogenic mechanisms associated with 
MYH11 mutations. Some initial insight can be gained, however, through studies on 
mutations in other myosin heavy chain isoforms. Mutations in cardiac-specific α-actin and 
β-myosin cause familial hypertrophic cardiomyopathy (92). The disease is characterized by 
myocyte disarray and hypertrophy, and accumulation of extracellular matrix (92). 
Additionally, increased levels of mitotic and trophic factors, including insulin-like growth 
factor 1 (IGF-1), transforming growth factor β1 (TGF-β1), and platelet-derived growth 
factor β (PDGF-B) have been found in the myocardium of a subset of HCM patients (93-
95). It has been hypothesized that altered cardiac contractility leads to increased production 
of growth factors, which may in turn play a role in HCM pathogenesis (96;97). Long-term 
overexpression of IGF-1 in mouse hearts leads to a phenotype of cardiac hypertrophy, 
extracellular matrix accumulation, and myocyte disarray compared with wild-type hearts, 
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consistent with this hypothesis (98). Angiotensin II (Ang II) signaling may also contribute to 
HCM pathogenesis. AngII contributes to cardiac hypertrophy, and involvement of a renin-
angiotensin system in pathogenesis of HCM has been reported (99;100). Specifically, ACE 
polymorphisms leading to increased ACE expression and concomitant increases in 
hypertrophy in individuals with HCM have also been reported (101). However, others have 
failed to find any association (102).  
The same growth factors that are increased in HCM patients (TGF-β, PDGF, and 
IGF-1) also induce proliferation in SMCs (103). This suggests that the contractile defect 
may lead to the production and release of growth factors which, along with other stimuli, 
may be driving increased cellular proliferation in focal areas of the diseased tissue. 
Therefore, we hypothesized that MYH11 patients’ pathology is similar to the pathology 
observed in HCM.  
 
Materials and Methods 
SMC isolation and culture 
 All studies involving human subjects were approved by the institutional review 
board at the University of Texas Health Science Center at Houston (UTHSCH), and 
informed consent was obtained from all study participants. SMCs, frozen aortic tissue, and 
paraffin-embedded tissue were obtained from one patient heterozygous for two closely 
linked MYH11 mutations (L1264P and R1275L) and from controls who died of causes 
unrelated to vascular disease, and were processed according to an established protocol (21). 
An available H&E slide from a second patient heterozygous for a MYH11 R712Q mutation 
was also obtained. Adventitial and intimal layers were removed from the aortic tissue. The 
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remaining medial tissue was minced and digested in Waymouth’s media (supplemented with 
2.5 mM L-glutamine, 1 mM MEM non-essential amino acids, 100 mM Hepes buffer, 
sodium bicarbonate, and 1x antibiotic/antimycotic) and an enzyme mixture containing 
elastase type I (0.01875mg/mL), collagenase type I (0.1mg/mL), and soybean trypsin 
inhibitor (0.025 mg/mL). After 16 hours of incubation, enzymes were inactivated using FBS 
followed by SmBm containing insulin, rhEGF, rhFGF, antibiotic/antimycotic, and 15% FBS 
(Lonza). After centrifugation to remove remaining adventitial fat and any remaining 
Waymouth’s media, tissue pieces were seeded into T25 flasks, and allowed to adhere for 4-6 
weeks until SMCs migrated out of the tissue. SMCs were cultured in complete SmBm and 
passaged upon confluence.  
 
RNA isolation 
 Cells were seeded at confluence into 60 mm dishes and allowed to adhere overnight. 
Cells were harvested following 18 hours of serum starvation (in media containing antibiotics 
only and not supplemented with serum or growth factors), and RNA was isolated using 
phenol-chloroform extraction (Trizol or Tri Reagent), according to the manufacturer’s 
instructions. RNA samples were randomly tested for quality and purity using an Agilent 
Bioanalyzer. If necessary, RNA was purified using the RNeasy mini kit according to the 
manufacturer’s instructions (Qiagen).  
 RNA was isolated from whole tissue using a similar phenol-chloroform extraction 
protocol. Briefly, small pieces of frozen tissue were minced in Trizol solution (Invitrogen) 
and then homogenized using a Polytron tissue homogenizer. Samples were centrifuged at 
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high speed for 30 minutes at 4ºC to remove tissue pieces. Supernatants were transferred to 
new tubes, and RNA isolation was continued according to the manufacturer’s instructions.  
 
Gene expression analysis 
 50ng of total RNA from each sample was reverse transcribed in triplicate using a kit 
from Applied Biosystems. Quantitative PCR was carried out using pre-designed Taqman 
gene expression assays (Applied Biosystems, Foster City, CA) on either an ABI 7000 or 
ABI 7700 according to the manufacturer’s instructions, with the exception that the final 
reaction volume was 20µL instead of 50µL. Thermal cycling parameters were as follows: 
95.0ºC for 10 minutes, followed by 40 cycles of 95.0ºC for 15 seconds and 60.0ºC for 1 
minute. Relative gene expression levels were calculated using the ∆∆CT method, using 
GAPDH as an endogenous control. Student’s T-tests were used to determine statistical 
significance.  
 
Histology 
 H&E and Movat’s pentachrome stains were provided by the University of Texas-
Medical School pathology core and Texas Heart Institute pathology core, respectively. 
Toluidine blue staining of cells was also performed by the UT pathology core.  
 Immunostaining of paraffin-embedded sections was performed as follows. Tissues 
were deparaffinized and rehydrated using a series of xylene, ethanol, and PBS washes for 
2x5 minutes for each wash: xylene, 100% EtOH, 95% EtOH, 70% EtOH, and 1x PBS. 
Antigen retrieval was accomplished using 10mM citrate buffer, pH=6.0. Sections were 
submerged in citrate buffer and microwaved at 50% power for 9 minutes, followed by 1 
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minute at full power. Sections were monitored carefully to ensure that they did not dry out. 
Following antigen retrieval, sections were allowed to cool in citrate buffer for 40-60 
minutes. Sections were blocked for 1 hour at room temperature in normal serum from the 
same species used to generate the secondary antibody (Vector Labs), and were incubated 
with primary antibody overnight at 4ºC (Table 1).  
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Table 1. Antibodies and dilutions. 
Primary antibodies 
antibody company species IB IHC IF 
β-actin Sigma mouse   1:100 
CD3 
Santa 
Cruz rabbit  1:50   
CD68 
Santa 
Cruz rabbit  1:50   
CTGF 
Santa 
Cruz rabbit  1:50   
p-ERK1/2 
Cell 
Signal rabbit 1:1000    
ERK1/2 
Cell 
Signal rabbit 1:1000    
pY397 FAK Millipore mouse 1:750  1:50 
FAK 
Santa 
Cruz rabbit 1:500    
Gapdh Abcam rabbit 1:2000    
Gapdh Fitzgerald mouse 1:20,000    
IGF-1 
Santa 
Cruz rabbit  1:25   
SM α-actin Sigma mouse 1:5000 1:200 1:100 
PAI-1 
Santa 
Cruz rabbit  1:50   
PCNA Zymed mouse  pre-diluted   
phalloidin-Texas Red Invitrogen n/a   1:40 
pSmad2/3 
Santa 
Cruz rabbit  1:50   
tensin 
Santa 
Cruz rabbit  1:25   
vinculin Sigma mouse-FITC   1:500 
von Willebrand factor Dako rabbit  1:200   
zyxin 
Santa 
Cruz goat     1:25 
Secondary antibodies and fluorophores 
antibody or fluorophore company application dilution  
rabbit-HRP Jackson Immunoresearch IB 1:2000-1:5000   
mouse-HRP Jackson Immunoresearch IB 1:2000-1:20,000   
goat-AP Santa Cruz IF 1:100   
mouse-AP Vector Labs IHC 1:200   
rabbit-AP Vector Labs IF, IHC 1:100-1:200   
mouse-FITC Jackson Immunoresearch IF 1:100-1:200   
Fluorescein-streptavidin Vector Labs IF 1:100   
Texas Red-streptavidin Vector Labs IF 1:100   
 
************************************************************************ 
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The following day, tissue sections were washed 2x in PBS and incubated with the 
appropriate secondary antibody (Vector Labs) for 1 hour at room temperature, at a 1:200 
dilution. Sections were washed 2x in PBS, incubated for 1 hour with a working dilution of 
avidin-biotin conjugating reagent (Vector Labs), and washed 2x in PBS. A Vector Red 
substrate kit was used to visualize immunostaining, and sections were counterstained with 
hematoxylin, dehydrated, and mounted with coverslips using Permount (Fisher). Specimens 
were viewed and photographed using an Olympus BX60 microscope (Olympus). Images 
were processed and prepared for publication using Adobe Photoshop 6.0.  
 For toluidine blue staining, SMCs were seeded at a density of 5000 cells per 22 mm 
glass coverslip, allowed to attach overnight, serum starved for 24 hours, and fixed with 4% 
paraformaldehyde for 10 minutes. Toluidine blue staining was performed by the 
Histology/IHC Laboratory at The University of Texas Medical School.  
 
TGF-β1 treatment of SMCs and immunofluorescence 
 SMCs were seeded onto 22 mm glass coverslips at a density of 5,000 cells per 
coverslip and allowed to attach overnight before serum starving. Following 24 hours of 
serum deprivation, media was replaced with fresh serum-free media containing TGF-β1 
(5ng/mL). Cells were fixed in 4% paraformaldehyde 72 hours post-TGF-β1 treatment. 
Coverslips were blocked for 30 minutes in PBS containing 1% BSA and 0.1% Tween20, 
and incubated overnight with primary antibody at 4ºC. The following day, coverslips were 
incubated with a FITC-conjugated mouse secondary antibody (1:200, Jackson 
Immunoresearch, West Grove, PA) for one hour followed by Texas Red-conjugated 
phalloidin for 30 minutes, and were mounted onto slides with Vectashield mounting medium 
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with DAPI (Vector Labs, Inc., Burlingame, CA). Table 1 lists antibody and fluorophore 
concentrations used. Immunofluorescently labeled SMCs were viewed and photographed 
using an Axioskop40 microscope, Axiocam MRm camera, and Axiovision software (Zeiss, 
Thornwood, NY).  
 
Cell counting 
 Ten high-powered fields (400x) were photographed of each SM α-actin stained 
aortic tissue sample from two controls, and from the sinuses of Valsalva and ascending aorta 
of the MYH11 patient. SM α-actin positive cells from the high-powered fields were counted 
and averaged. To assess the number of actively proliferating cells, similar photographs were 
taken of ten high-powered fields from each PCNA stained aortic tissue from patient and 
controls. Both the total number of cells and the number of PCNA positive cells from each 
section were counted, and the percent of actively proliferating cells was calculated. Data are 
represented ± S.D., and statistical significance was determined using a Student’s T-test.  
 
Organ culture and ELISA 
 A previously established protocol was used in order to assess the secretion of 
cytokines from whole aortic tissue of patients and controls (104;105). Stock solution of ITS 
was prepared, containing 0.5mg/mL insulin, 0.5 mg/mL transferrin, and 0.5 µg/mL sodium 
selenite (Sigma-Aldrich, Inc.). 10µl of ITS stock solution was added to 990ul DMEM 
containing 0.1% BSA. Whole aortic tissue segments from the MYH11 patient and two 
unaffected controls were isolated, excess fat tissue was removed, and tissue was weighed to 
ensure that equal amounts of tissues were used for the organ culture. Aortas were completely 
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submerged and incubated in the DMEM-ITS solution for 3 hours at 37ºC. The tissue culture 
supernatant fraction was collected and immediately frozen in 200µL aliquots and stored at -
80ºC until analysis. Secretion of a panel of cytokines was analyzed using a Bio-Plex 
Suspension Array System (Bio-Rad Laboratories, Inc.), and was performed as previously 
described (104). An ELISA was performed to quantify Ang II production. Organ culturing 
was performed by Dr. Yaozhong Liu, and the Bio-Plex cytokine assay and Ang II ELISA 
were performed in collaboration with the Brasier lab at University of Texas Medical Branch 
in Galveston.  
 
Results 
Unique vascular pathology in two patients heterozygous for MYH11 mutations 
 Staining of aortic tissue with Movat’s pentachrome stain provided the advantage of 
being able to visualize multiple components of the vascular wall simultaneously. This stain 
labels cells red, proteoglycans blue, collagens yellow, elastic fibers black, and nuclei violet, 
allowing for rapid identification of various features of medial degeneration. Aortic tissue 
from one patient heterozygous for two closely linked MYH11 missense mutations (L1264P 
and R1275L) showed typical features of medial degeneration, including fragmentation of 
elastic fibers, accumulation of proteoglycans, and some areas of SMC loss, consistent with 
findings by Zhu et al (33). SM α-actin immunoreactivity also appeared to be normal in these 
tissues (data not shown). H&E staining of aortic tissue was available from one additional 
patient heterozygous for a different MYH11 mutation (R712Q). In contrast to both the 
control aorta and the aorta of a patient with Marfan syndrome, both aortas from patients with 
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MYH11 mutations displayed areas of SMC accumulation within the medial layer (Figure II-
1).  
 
Figure II-1. Aortic pathology associated with MYH11 mutations. H&E staining showed 
normal alignment of SMCs in control (A) and a Marfan patient (B), but focal areas of SMC 
hyperplasia and disarray in two MYH11 patients (C, R712Q mutant and D, L1264P mutant). 
SMC hyperplasia was particularly apparent in the vasa vasorum of the MYH11 patient. H&E 
staining of control (E) and MYH11 L1264P mutant (F) aortic tissue showed enlargement of 
the vasa vasorum coupled with luminal narrowing in some vessels, whereas other vessels 
appeared normal, as indicated by arrows. SM α-actin staining revealed normal vasa vasorum 
in the control (G), and confirmed that vessel thickening in the MYH11 patient was due to 
SMC hyperplasia (H). Movat staining of the aortic media from control (I) and patient (J) 
showed typical features of medial degeneration in the MYH11 patient, including 
proteoglycan accumulation (blue), fragmentation and loss of elastic fibers (black), and focal 
areas of SMC loss. Von Willebrand factor staining showed that the MYH11 patient had a 
dramatic increase in the number of small vessels penetrating deep into the medial layer (L) 
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compared with controls (K). Scale bars represent 100 µm. Reprinted by permission from 
Oxford University Press (36), copyright (2007).  
************************************************************************** 
Additionally, SMCs in areas of the media were oriented in random directions, in contrast to 
controls, which had SMCs and elastic fibers organized in concentric layers perpendicular to 
the axis of mechanical stretch. Although hyperplasia has been reported in TAA 
development, aneurysms are often characterized by SMC loss (19;80;82). The combination 
of hyperplasia and cellular disarray represent a novel aortic phenotype in TAAD patients.   
 In addition to cellular disarray and accumulation in the media, a number of vessels in 
the vasa vasorum of the MYH11 patient heterozygous for an L1264P mutation showed 
enlargement and thickening, based on H&E staining. Staining for SM α-actin and 
counterstaining for nuclei confirmed that this thickening is due to SMC proliferation 
(Figure II-1). Thickening occurred in some, but not all, of the vasa vasorum, suggesting that 
the contractile mutation is the primary defect, and a secondary insult to the vessel wall 
triggers the hyperplastic response.   
 At the time of surgical aortic repair, the surgeons noted an unusual, visible increase 
in vascularity in this particular patient. Von Willebrand staining, specific for endothelial 
cells, was used to confirm the increased vascularity. In normal aortic walls, the vasa 
vasorum are mainly confined to the adventitia and the adventitia-media border. In sharp 
contrast to controls, the MYH11 patient showed a dramatic increase in the number of small 
blood vessels penetrating into the medial SMC layer of the aortic wall (Figure II-1).  
 
Increased proliferation and accumulation of SMCs in the MYH11 aorta 
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 Counting of SM α-actin positive cells in aortic tissue sections from the ascending 
aorta of two controls, and sections taken from the sinuses of Valsalva and from the 
ascending aorta in the MYH11 patient revealed a significant increase in cell number in the 
patient’s aorta (Figure II-2). 
  
Figure II-2. SMC hyperplasia and increased SMC proliferation due to MYH11 mutations.  
(A) Significantly greater numbers of SM α-actin positive cells were found in MYH11 aortic 
tissue, and this was consistent for tissue taken either from the aneurysmal portion of the 
aorta or from the sinuses of Valsalva. (B) Immunostaining of tissues with PCNA, a 
proliferative marker, showed a significantly higher percentage of actively proliferating 
SMCs in the medial layer of the patient’s aneurysmal tissue compared with controls and 
with the sinuses of Valsalva. Error bars represent S.D. **p<0.01. Reprinted by permission 
from Oxford University Press (36), copyright (2007). 
************************************************************************** 
** 
** 
** 
** 
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This observation was significant both in the undilated aortic root (sinuses of Valsalva) and 
in the aneurysmal portion of the aorta (ascending). These data confirm that the increase in 
cellularity is due to increased numbers of SMCs rather than inflammatory cells or a different 
cell type. To determine whether these cells represented actively proliferating SMCs, we 
immunostained the cells for PCNA, a nuclear marker for actively proliferating cells, and 
counted the number of PCNA positive nuclei as well as the total number of nuclei under 
high power magnification. A significantly higher percentage of SMCs in the patient’s 
ascending aorta, at the site of aneurysm formation, were actively proliferating, compared 
with the controls (p<0.01). However, although increased nuclei were present in the patient’s 
sinuses of Valsalva, no significant difference in the percent of PCNA positive cells was 
found between the sinuses and the controls. There was a significantly higher percentage, 
however, in the number of actively proliferating cells in the patient’s ascending aneurysm 
compared with the patient’s sinuses of Valsalva (p<0.01). Although myocyte hypertrophy is 
one of the hallmark features of HCM, toluidine blue staining did not reveal any apparent 
differences in cell size in the MYH11 patient compared with controls (data not shown).  
 
Increased IGF-1 but not TGF-β1 or PDGF-B expression 
 Since TGF-β1, PDGF-B, and IGF-1 were all reported to be increased in tissues of 
HCM patients, we analyzed expression of these growth factors in our explanted SMCs, as 
well as in whole frozen aortic tissue samples (93-95). IGF-1 transcript levels were 
significantly increased in the patient’s SMCs, and IGF-1 immunoreactivity was increased in 
the patient’s aortic tissue compared with controls. TGF-β1 was not increased, and PDGF-B 
was decreased compared with the controls (Figure II-3).  
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Figure II-3. IGF-1 and ACE expression are increased in MYH11 mutant SMCs and tissues. 
(A) IGF-1 gene expression is significantly increased in SMCs explanted from the MYH11 
mutant aorta compared with controls. In contrast, TGF-β1 and PDGF-B levels are not 
significantly altered. (B) ACE gene expression is significantly increased in MYH11 SMCs 
compared with controls. In contrast, other RAS components including renin (REN), 
angiotensinogen (AGT), and angiotensin II type I receptor (AT1R) are not significantly 
altered. Gene expression data are normalized to GAPDH, and error bars represent S.D. 
*p<0.05. (C-F) IGF-1 immunoreactivity was increased in both the aortic media and 
* 
* 
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hyperplastic vessels in the adventitia in the MYH11 tissue (D,F) compared with control 
(C,E). Reprinted by permission from Oxford University Press (36), copyright (2007).  
************************************************************************* 
Increased TGF-β1 activation has been reported in aneurysms in a mouse model of Marfan 
syndrome; therefore, we sought to determine whether pathways downstream of TGF-β1 
were activated in the MYH11 cells and tissue (10). Phosphorylated Smad2/3 is an early 
marker of activated TGF-β1 signaling; however, we did not find any difference in Smad2/3 
phosphorylation in the patient aorta compared with controls (data not shown). 
Immunostaining for two other downstream markers of TGF-β1 signaling, CTGF and PAI-1, 
also failed to reveal any difference in TGF-β1 activation (data not shown). These data 
suggest that TGF-β1 signaling is not increased in the MYH11 aorta. However, IGF-1 
immunoreactivity was increased in the patient’s aortic tissue compared with controls 
(Figure II-3). Thus, IGF-1 but not TGF-β1 or PDGF-B, is increased in response to MYH11 
mutations.  
 
Potential role for a local renin-angiotensin system in the disease process 
 Although the majority of IGF-1 in the body is produced in the liver and circulates 
throughout the body, IGF-1 can also be locally produced in an autocrine/paracrine manner. 
IGF-1 expression can be upregulated through multiple pathways in SMCs, including through 
mechanical stress, oxidative stress, growth factor signaling, and Ang II-mediated signaling 
(106). We also analyzed production of pro-angiogenic and pro-proliferative cytokines using 
a multiplex ELISA, and found striking increases in MIP-1-α and MIP-1-β. MIP-1-α is of 
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particular interest because Ang II infusion results in increased MIP-1-α production in the 
aorta (104) (Figure II-4A).  
 
Figure II-4. MIP-1α and MIP-1β expression are increased in MYH11 SMCs and tissues. 
(A) Organ culture followed by a Bio-Plex cytokine assay revealed increased secretion of 
MIP-1α and MIP-1β from the MYH11 aorta (n=1) into the culture media compared with 
controls (n = 4). Concentrations are expressed in units of pg/mL. (B,C) MIP-1α and MIP-1β 
gene expression were increased in MYH11 SMCs and aortic tissue, compared with controls. 
Error bars represent SD. Bio-Plex cytokine assay was performed by Dr.Yao-Zhong Liu in 
collaboration with The University of Texas Medical Branch at Galveston. Reprinted by 
permission from Oxford University Press (36), copyright (2007). 
************************************************************************** 
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QPCR analysis of explanted SMCs and aortic tissues confirmed an increase in gene 
expression of these cytokines, suggesting that these are being produced specifically by 
SMCs rather than other cell types in the aortic wall (Figure II-4B,C). MIP-1α is expressed 
in response to angiotensin II signaling, leading us to hypothesize that a local renin-
angiotensin system is contributing to the observed increase in IGF-1. Gene expression of 
renin-angiotensin system components in aortic tissue and explanted SMCs showed an 
increase in angiotensin-converting enzyme, but not renin, angiotensinogen, or angiotensin II 
type I receptor. Data from explanted SMCs are shown in Figure II-3; data from whole 
aortic tissue was consistent with the explanted SMCs. Due to the dramatic increase in ACE 
expression, we expected to also find increased secretion of angiotensin II by the MYH11 
SMCs. However, an angiotensin II ELISA, as well as angiotensin II immunostaining of 
aortic tissue, failed to show a difference in angiotensin II secretion by the whole aortic tissue 
section (data not shown).  
 
Inflammation and MYH11 TAAD 
 Vascular wall inflammation is present in a subset of TAAD and may play an 
important role in pathogenesis. Since MIP-1α and MIP-1β are inflammatory cytokines and 
both the secreted cytokines as well as mRNA levels were increased in the MYH11 patient, 
we hypothesized that inflammation is present in MYH11 TAAD pathogenesis. MIP-1α is 
produced by macrophages; therefore, we hypothesized that medial tissue in the MYH11 aorta 
would contain significant numbers of macrophages compared with control tissues. However, 
immunostaining for CD3, a T-cell antigen, and CD68, a macrophage marker, did not reveal 
any major inflammation. Counting of CD68 positive cells under high-powered fields failed 
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to reveal a significant difference in the numbers of macrophages in the patient vs. the 
controls (data not shown).  
 
Disruption of contractile filament assembly or stability 
 The missense mutation L1260P is predicted to disrupt the structure of MYH11. This 
mutation is located in the coiled-coil domain of the protein and is predicted to disrupt coiled-
coil formation and/or stability (36). However, it was not known whether alterations in the 
myosin filaments disrupted the structure of other contractile proteins within the cell. Initial 
immunofluorescent staining did not show strong SM α-actin labeling; therefore, SMCs were 
treated with TGF-β1, a known inducer of SMC differentiation, to induce increased 
expression of contractile proteins. 72 hours post TGF-β1 treatment, MYH11 SMCs 
expressed SM α-actin, but the actin was not organized into contractile filaments within the 
cell, in contrast with controls (Figure II-5). These data support the idea that disrupting one 
element of the contractile apparatus also disrupts other contractile elements within the cell 
and ultimately leads to decreased contractile function.   
 
Filamentous actin α-SM actin Merge, nuclei 
control 
MYH11 
L1250P 
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Figure II-5. Decreased SM α-actin polymerization in MYH11 SMCs. Explanted control and 
MYH11 mutant SMCs were treated with 5ng/mL TGF-β1 to enhance SM α-actin expression, 
after initial immunostaining for SM α-actin failed to yield results. Phalloidin-labeled actin 
filaments (red) remained unaltered in the mutant SMCs; however, SM α-actin filaments are 
disrupted in the MYH11 mutant SMCs. Focal areas of SM α-actin staining were observed, 
suggesting that filaments begin to form but are prohibited by defective MYH11 from fully 
assembling by within the cell.  
************************************************************************** 
 
Discussion 
 We have described a novel pathology associated with MYH11 mutations, including 
SMC hyperplasia and disarray in the aortic wall, hyperplastic vasa vasorum, and increased 
IGF-1 expression, in addition to typical features of medial degeneration. The observed 
disarray, growth factor production, and ECM accumulation were similar to findings in HCM 
patients, with the exception that proteoglycan rather than collagen was increased in the 
MYH11 patient. In contrast to HCM, we observed SMC hyperplasia rather than hypertrophy. 
This hyperplasia is significant because some controversy exists over whether SMC loss or 
SMC hyperplasia occurs in aortic aneurysms (80-82). In one study, SMC loss was reported 
in approximately 50% of TAAs (19). Another study showed that SMC loss was important, 
but the study focused on abdominal aneurysms, which differ from TAA in their etiology and 
pathogenesis (80). More recently, a different study suggested that SMC hyperplasia is an 
initial adaptive response during early stages of aneurysm formation (82). This idea is 
supported by the fact that SMC hyperplasia was observed in the vasa vasorum of the MYH11 
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patient, who had a rapidly expanding aneurysm at the time of surgical repair. Therefore, 
identifying the pathways leading to SMC hyperplasia is important for understanding familial 
TAAD.  
 Others have reported abnormal thickening of the vasa vasorum in thoracic aortic 
aneurysms, and blockage of the vasa vasorum renders the aorta more prone to dissection 
(19). The extent of vasa vasorum thickening appeared to be greater in the MYH11 patient 
than in patients with FBN1 or TGFBR2 mutations, however. Future studies will determine 
whether an increased amount of vasa vasorum thickening is commonly present in 
individuals with mutations in other SMC-specific contractile genes.  
 In addition to SMC hyperplasia, the marked increase that we observed in IGF-1 
warrants follow-up for several reasons. First, IGF-1 can be locally produced by SMCs, and 
multiple studies have demonstrated that this leads to an increase in cell proliferation. For 
example, treatment of rat vascular SMCs with exogenous IGF-1 induced an increase in 
proliferation, and this effect was inhibited with an IGF-1 neutralizing antibody. 
Additionally, exposing the rat SMCs to cyclic stretch caused both an increase in IGF-1 
secretion and in cellular proliferation, which was also blocked by treatment with an IGF-1 
antibody (107). Second, in addition to its role in SMC proliferation, IGF-1 plays an 
important role in regulating contractility. Aortas from mice that chronically overexpress 
IGF-1 generate more force when contracting than wildtype mouse aortas. Overexpression of 
an inhibitor of IGF-1 action, IGF binding protein 4 (IGFBP4), prevents this increase (108). 
Additionally, IGF-1 causes an increase in both α-actin and myosin expression in vascular 
SMCs (108;109) The dual role for IGF-1 in SMCs, together with data from the MYH11 
patient, suggest that IGF-1 may be increased in response to improper contractile filament 
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assembly or stability, and may play a role in driving the observed SMC proliferation. 
Further, the fact that IGF-1 can be pathologically increased in response to vascular injury 
further emphasizes its potential importance in pathogenesis of TAAD in MYH11 patients. 
For example, IGF-1 levels were increased in rat aortas that were surgically banded near the 
renal artery to induce hypertension (110). Also, IGF-1 levels are increased in response to 
arterial balloon injury (111;112). Additional studies have shown that increased IGF-1 levels 
are capable of causing increased proliferation in response to vessel injury. In mice that are 
genetically modified to overexpress IGF-1 in SMCs, disruption of the endothelium in the 
carotid artery leads to increased SMC proliferation and migration (113).  
 Unexpectedly, experimental evidence suggested a potential role for a local renin-
angiotensin system in MYH11 disease pathogenesis. The increase in ACE expression by 
explanted SMCs, along with increased secretion of MIP-1α, suggest that Ang II production 
and signaling are increased in the MYH11 patient. Ang II is known to induce cardiac 
hypertrophy, as well as SMC proliferation. Additionally, Ang II infusion is an established 
model of abdominal aneurysms (114). However, contribution of a local renin-angiotensin 
system is difficult to assess, and conflicting data exist as to whether alterations in renin-
angiotensin system components are associated with HCM. ACE is a circulating enzyme and 
is secreted by endothelial cells. Therefore, it is possible that ACE expression is due to the 
increased vascularity observed in the MYH11 patient. However, the fact that explanted 
SMCs specifically express increased ACE does not support this possibility. Primary 
endothelial cells are technically difficult to isolate and culture, and as much endothelium and 
adventitia as possible are scraped away during SMC isolation; thus, the SMC explant 
protocol used is unlikely to result in contamination of SMC culture with endothelial cells. It 
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is also possible that the increased ACE expression in the MYH11 patient is due to a 
polymorphism coincidental with the MYH11 mutation, similar to some cases of HCM (101). 
The ACE gene was not tested for polymorphisms in this individual.    
 In contrast to findings in mouse models of Marfan syndrome, we did not find 
evidence of increased TGF-β1 signaling in the MYH11 patient. TGF-β1 mRNA expression 
was not significantly altered. Phosphorylated Smad2/3, an early marker for activated TGF-
β1 signaling, was not increased in the patient’s aortic tissue. Additionally, the expression of 
CTGF and PAI-1, two proteins known to be increased in response to TGF-β1 signaling, 
remained unaltered. These data suggest that additional mechanisms other than dysregulated 
TGF-β1 signaling are driving the disease process due to MYH11 mutations. The observed 
increase in IGF-1, together with the established roles for IGF-1 in promoting SMC 
contractility and proliferation, suggest a potential role for IGF-1 in MYH11 disease 
pathogenesis.  
 Interestingly, in addition to TAAD and PDA, patients heterozygous for MYH11 
mutations are also more likely to develop major occlusive cardiovascular diseases than 
unaffected family members, in the absence of other cardiovascular risk factors. In our 
families with identified MYH11 mutations and in the large French family originally used to 
identify the mutations, 19% of individuals heterozygous for the mutation (5 out of 26) 
developed either early onset stroke or early onset CAD, but these diseases were absent in the 
family members who did not carry the mutation (Pannu et al, manuscript submitted). 
Additionally, MYH11 mutations have been identified in patients with other forms of vascular 
disease, including 3 different missense mutations in individuals with premature CAD, 5 
alterations (3 novel and 2 present in CAD) in individuals with early onset stroke, and 7 
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alterations in individuals with Moyamoya disease, which is a pediatric-onset ischemic stroke 
syndrome due to intimal fibrocellular accumulation in arteries in the circle of Willis (Pannu 
et al, manuscript submitted) (115). 
 One advantage of this study is that we were able to gain insight into aneurysmal 
disease at its peak of progression, in contrast to many other tissue samples that are obtained 
when the disease is more in its end stages. Although the mutation is rare and the sample size 
for this study was very small, the fact that the tissue sample came from a very rapidly 
expanding aorta provided us with a unique opportunity to gain insight into the disease 
process, as well as generate new hypotheses for follow-up in other TAAD patients. While 
we were conducting this study, mutations in multiple other SMC-specific contractile genes 
were identified, and the data obtained from this study was able to provide a starting point for 
analysis of subsequent contractile gene mutations.  
 One limitation of this study is that we did not directly assess disruption of myosin 
contractile filaments in MYH11 mutant SMCs, either by immunofluorescence, due to 
technical difficulties with antibody staining, or by assessing myosin motor activity through 
ATPase assays. However, several lines of evidence, including more recent studies on several 
MYH11 mutants, exist that argue in favor of the mutation disrupting contractile filaments. 
First, both software-predicted evidence and in vitro data exist to suggest that contractile 
function is disrupted. COILS software predicted a decrease in the probability of coiled-coil 
formation in L1260P mutant MYH11 (36). The R712Q mutation is paralogous to a myosin 
IIA mutation that has already been shown to uncouple ATPase activity from the myosin 
motor as well as disrupt the thermal stability of the protein, contractile filaments are highly 
likely to be disrupted by this mutation as well (36). Additionally, previous reports of MYH11 
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mutations show a predicted disruption in coiled-coil formation as well as increased 
denaturation of MYH11 filaments after formalin fixation, indicative of a less stable protein 
(33). More recent in vitro assays have shown that a number of MYH11 mutations in the 
ATPase head domain have reduced ATPase activity compared to wildtype (Pannu et al, 
manuscript submitted). Second, immunofluorescence data suggest that SM α-actin filament 
formation and/or stability is disrupted in the MYH11 mutant SMCs. The stoichiometry of 
components of the contractile apparatus is highly regulated, and disruption of one 
component easily leads to disruption of other components (116). This idea is supported by 
the observation that Acta2-/- mouse aortas display fewer myosin thick filaments than 
wildtype, as assessed by electron microscopy (117). Therefore, MYH11 contractile 
filaments are likely to be disrupted by the mutations described in this study.  
 It is still unknown whether the MYH11 SMCs are inherently more proliferative due 
to structural alterations in the cell, or whether the observed proliferation is caused by 
increased cellular stress and release of growth factors secondary to loss of cellular 
contractility and loss of elastic fibers in the aortic wall. However, current data as well as 
previous studies suggest that cell proliferation may play a key role in disease formation in 
these individuals, and that IGF-1 may be a key factor in this process. While we cannot 
completely exclude the involvement of other growth factors in the progression of this 
disease, we propose that a decrease in SMC contractility and subsequent increase in cellular 
stress induces the SMCs to overproduce IGF-1. The primary defect in the contractile 
apparatus in the cell may hinder the ability of IGF-1 to increase contractility, while still 
allowing for IGF-1-induced proliferation. Future studies will provide insight into the 
mechanism and role of increased IGF-1 expression by aortic SMCs in the pathology of 
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familial TAAD due to MYH11 mutations, as well as other mutations that result in a similar 
vascular pathology.  
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CHAPTER III 
CHARACTERIZATION OF THE VASCULAR AND CELLULAR PHENOTYPE IN 
TAAD PATIENTS HETEROZYGOUS FOR ACTA2 MUTATIONS 
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Background 
 Six different actin isoforms have been identified: SM α-actin (ACTA2), cardiac α-
actin (ACTC), skeletal α-actin (ACTA1), smooth muscle γ-actin (ACTG2), cytoplasmic γ-
actin (ACTG1), and cytoplasmic β-actin (ACTB) (118;119). The various actin isoforms are 
highly homologous, with greatest variability found near the N-terminus, but are not 
functionally redundant. SM α-actin comprises approximately two thirds of total actin and 
40% of total protein within SMCs, making it the single most abundant protein in this cell 
type (120;121). 
 Several studies have shown that actin isoforms can partially but not fully compensate 
for loss of one isoform. Expression of Actg2 rescues the lethality in Actc-/- mice, and 
partially but does not fully restore cardiac structure and function. Expression of Actc but not 
Actg1 rescues the early postnatal lethal phenotype in Acta1-/- mice, demonstrating that in 
some cases one actin isoform can potentially be substituted for another (122;123). Some 
cardiac α-actin is expressed in humans in the absence of skeletal α-actin; however, the 
cardiac α-actin expression is unable to prevent disease in these individuals. The exact 
mechanisms determining specificity of each actin isoform are not known. All of these 
studies provide support for the idea that defects in the SM α-actin protein cannot be 
compensated for simply by the presence of other actin isoforms within SMCs.  
Acta2-/- mice demonstrate decreased vessel contractility, underscoring the 
indispensability of SM α-actin for proper SMC contraction (117). Surprisingly, complete 
deletion of SM α-actin does not disrupt development of the cardiovascular system.  
Increased expression of Acta1 and Actg2 in vascular SMCs in these mice was identified, 
presumably to compensate for the loss of ACTA2 (117;124). 
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 Other actin isoforms play an important role in SMC contraction as well. β-
cytoplasmic actin and γ-actin make up 21% and 13% of total actin in vascular SMCs, 
respectively (120). Some debate exists over whether the various actin isoforms in SMCs can 
polymerize into the same actin filaments, or whether actin isoforms are compartmentalized 
within the cell (125;126).  
 The discovery of MYH11 mutations leading to TAAD, along with novel pathologic 
findings associated with these mutations, led to the following questions: Are additional 
SMC-specific contractile proteins altered in TAAD? If so, do mutations in these other 
contractile proteins lead to a similar vascular pathology? Subsequent identification of 
mutations in SM α-actin provided answers to some of these questions. ACTA2 missense 
mutations in TAAD were identified through linkage analysis and positional cloning (34). A 
large family was recruited for study but did not have mutations in FBN1, TGFBR2, or 
MYH11, and was not linked to any other known TAAD loci. The putative gene was mapped 
to chromosome 10q23-24 using an Affymetrix array followed by microsatellite markers for 
fine mapping of the critical interval. Twelve candidate genes were sequenced in the 
identified region, and a missense mutation in ACTA2, R149C, was identified. Sequencing of 
other familial TAAD samples revealed missense mutations at a total of eight different 
residues, in fourteen families, with recurrent mutations at R149C in five families, and 
R258C/R258H in three families (34). Additional mutations were subsequently identified 
both by our lab group and by others, including previously identified as well as novel 
mutations (83;127;128). Recently, de novo mutation of R179C leading to an exceptionally 
severe systemic clinical phenotype was identified in 5 unrelated children and young adults 
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(Dianna Milewicz, personal communication). All of the currently identified ACTA2 
mutations are predicted to produce a mutant protein from the altered allele.  
 ACTA2 mutations showed a dominant inheritance pattern with variable age of 
disease onset and decreased penetrance (34). A subset of ACTA2 mutation carriers also have 
PDA, livedo reticularis, or iris flocculi. Livedo reticularis is a condition caused by persistent 
occlusion of dermal capillaries leading to a purplish, netlike rash mainly on the upper and 
lower extremities, and iris flocculi are neoplastic cysts found in the iris. Since SMCs are 
present in the iris, it is possible that mutations in ACTA2 may both disrupt contractile 
function and enhance proliferation, leading to cyst formation (127). Surprisingly, the 
penetrance for TAAD caused by ACTA2 mutations was relatively low (0.48), even though 
the LOD score indicating that ACTA2 is indeed linked to TAAD was statistically significant, 
with a value of 4.17 (34).  
 The mutations in SM α-actin are located throughout the gene, and are predicted to 
have differing functional effects, with a common endpoint of disrupting actin 
polymerization (34). N117, R118, and V154 may disrupt either nucleotide binding or 
hydrolysis, and are located near the nucleotide binding cleft. Y135, R149, and T353 disrupt 
the binding site for various regulatory and end-capping proteins. R292 may disrupt actin 
polymerization due to its close proximity to residues involved in actin-actin interactions. 
R258 mutations are predicted to disrupt actin interactions with nebulin (34).  
 The presence of livedo reticularis in some ACTA2 patients led to the hypothesis that 
ACTA2 mutations cause vascular occlusive diseases in addition to TAAD. Upon 
examination of family medical histories, early onset CAD, stroke, and Moyamoya disease 
were found to segregate with ACTA2 mutations in affected families, and this was highly 
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statistically significant. Further, the disease penetrance rose from 0.48 to 0.80 when 
individuals with occlusive diseases were included in the analysis. When analyzed separately, 
each major vascular phenotype showed a positive LOD score for linkage to the ACTA2 gene, 
and the combined LOD score for all of the vascular phenotypes rose from 4.17 to 10.62 (83). 
Therefore, it was concluded that ACTA2 mutations cause vascular occlusive diseases in 
addition to TAAD. The fact that ACTA2 mutations are predicted to disrupt normal SMC 
contractile function suggests that decreased aortic contractility contributes to aneurysm 
formation. Interestingly, certain ACTA2 mutations are more highly associated with 
premature CAD than stroke, while other ACTA2 mutations are more associated with 
premature strokes and Moyamoya disease. Moyamoya disease is a bilateral occlusion of 
arteries in the circle of Willis due to SMC hyperplasia in the intimal layer of the vessel, and 
leads to early onset strokes (115). The most notable difference is between individuals with 
R149C mutations, which caused mainly TAAD and CAD, and individuals with R258C/H 
mutations, which caused mainly TAAD and stroke, along with Moyamoya disease (83).  
 Studies of mutations in other actin isoforms have provided valuable insight into 
mechanisms that may be driving disease in individuals with ACTA2 mutations. ACTC 
mutations cause idiopathic dilated cardiomyopathy and familial hypertrophic 
cardiomyopathy (129;130). Mutations in either ACTB or ACTG1 lead to deafness, and ACTB 
mutations also lead to developmental abnormalities and dystonia (131;132). ACTB 
mutations were also reported to cause severe mental retardation and recurrent infections 
(133). ACTA1 mutations cause skeletal myopathy, and more mutations have been found in 
ACTA1 than any other actin isoform to date (134;135). Studies of ACTC and ACTA1 
mutations provide the most valuable insight for our study, because several mutations in 
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these genes are homologous to a number of mutations identified in ACTA2 patients. Five 
mutations are found at homologous residues in both ACTA1 and in ACTA2 (34;83;135). 
Each of these mutations are predicted to disrupt function of ACTA1 (135). Due to the highly 
conserved nature of actins, these data, along with the fact that no polymorphisms have been 
identified in the ACTA2 gene, indicate that the alterations in ACTA2 are pathologic (34). 
Additionally, information gained from ACTA1 myopathies provide evidence that mutations 
in actin isoforms act in a dominant negative manner to disrupt contractile function of the cell 
(136).  
 Based these previous studies, the identified mutations in ACTA2 are predicted to 
disrupt structure and function of the protein in a dominant negative manner. However, little 
is known about the mechanisms underlying disease pathogenesis in these individuals. 
Dysregulation of TGF-β1 plays an important role in the pathogenesis of aneurysms in MFS 
(10). However mutations in MYH11, another contractile gene, did not lead to increased 
TGF-β1 signaling but did lead to SMC hyperplasia, suggesting that mutations in SMC-
specific contractile genes may result in a different mechanism of disease pathogenesis than 
previously described mutations. Our data from MYH11 SMCs and tissues suggest a novel 
proliferative pathology due to a contractile gene mutation, and subsequent studies identified 
early-onset vascular occlusive diseases in patients with MYH11 mutations (Pannu et al., 
manuscript submitted). ACTA2 is the second SMC-specific contractile gene identified 
leading to TAAD, and also causes early-onset occlusive diseases including CAD, stroke, and 
Moyamoya disease. As mentioned previously, Moyamoya disease results from a progressive 
stenosis of the internal carotid arteries due to intimal hyperplasia (115). Collectively, these 
data suggest that ACTA2 mutations should also lead to a proliferative pathology.  
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 In summary, damaging mutations exist in most other actin isoforms, and studies 
particularly in ACTA1 patients have shown evidence that the mutant protein disrupts 
contractile filament structure and interferes with the functioning of the remaining wildtype 
protein. Based on existing data in ACTA1 and ACTC mutant individuals and mice, and our 
pathologic findings in the aortas of patients with MYH11 mutations, we hypothesize that 
ACTA2 mutations disrupt SM α-actin filaments and lead to a proliferative vascular 
pathology similar to MYH11.  
 
Materials and Methods 
SMC explant and culture 
 All studies involving human subjects were approved by the institutional review 
board at the University of Texas Health Science Center at Houston (UTHSCH), and 
informed consent was obtained from all study participants. SMC explant, culture, and 
plating were performed as described in Chapter II.  
 
Histology, Immunofluorescence, and Microscopy 
 Aortic tissues from 9 patients heterozygous for ACTA2 missense mutations and from 
6 controls were obtained (Table 2). 
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Table 2. Tissue samples used for study 
aortic tissue samples 
pedigree ID mutation age sex ethnicity 
TAA105 II:4 R258H 49 F NE 
TAA166 II:2 Y135H 52 M NE 
TAA174 III:3 R118Q 47 M NE 
TAA313 II:2 T353N 49 M NE 
TAA327 III:19 R149C 36 M NE 
TAA327 IV:4 R149C 28 F NE 
TAA327 IV:5 R149C 26 M NE 
TAA455 II:11 R185Q 42 M H 
sporadic I250L 43 M NE 
coronary and cardiac samples 
pedigree ID mutation age sex ethnicity 
TAA441:IV:3 R118Q 28 M NE 
TAA441:III:6 R118Q 50 M NE 
TAA015:III:1 R292G 53 F NE 
controls 
control ID age sex ethnicity  
6437 48 F NE   
6701 68 F NE   
6625 47 M H   
2664 48 F NE   
7234 35 M H   
6559 69 M H   
Table 2. Tissue samples used for study. Sample ID, ACTA2 mutation, age, gender, and 
ethnic origin of patient and aortic and cardiac tissues, and control aortic tissues utilized for 
study are listed. (For ethnic origins, NE = Northern European descent; H = Hispanic).  
************************************************************************** 
Coronary artery tissue from one patient and cardiac tissue from two patients became 
available, and were also obtained and analyzed (Table 2). Histology and immunofluorescent 
staining were carried out as described in Chapter II. For high-resolution images of SM α-
actin staining, deconvolution microscopy was performed using a DeltaVision Deconvolution 
microscope system (Applied Precision, Inc.). Images were acquired and deconvolved using 
SoftWoRx 3.5 software. Images were obtained using 40x and 60x oil immersion objectives.  
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Cell proliferation assays  
 SMCs explanted from two patients heterozygous for ACTA2 missense mutations and 
from two controls were plated in triplicate at a density of 10,000 cells per well in a 9-well 
plate (Table 3).  
Table 3. Cell strains used for cell proliferation studies 
Smooth Muscle Cells 
Family Patient ID mutation age sex Control ID age sex 
TAA313 II:2 T353N 49 M MG8131 36 M 
sporadic MG5875 I250L 43 M MG8438 43 F 
Fibroblasts 
Family Patient ID mutation age sex Control ID age sex 
TAA018 III:1 P72Q 27 F MG3015 23 F 
TAA174 III:3 R118Q 47 M MG3032 26 M 
TAA327 IV:4 R149C 30 F MG3008 32 M 
TAA041 II:3 R149C 37 M MG3018 36 F 
TAA041 II:6 R149C 32 M MG3017 38 M 
TAA455 II:12 R185Q 42 M MG3019 41 F 
TAA455 II:8 R185Q 50 M MG3031 43 M 
TAA105 II:3 R258H 36 F MG3033 48 F 
TAA105 II:4 R258H 49 F MG3002 49 M 
          MG3027 53 F 
 
Table 3. Cell strains used for cell proliferation studies. Age denotes the age of the individual 
at the time that an aorta or skin biopsy was obtained. Reprinted from (83), with permission 
from Elsevier.  
************************************************************************** 
After 24 hours, cells were placed in SmBm containing 0.2% FBS, and 5-bromo-2-
deoxyuridine (BrdU), which replaces thymidine during DNA synthesis, was added. 24 hours 
post BrdU treatment, cells were fixed, and a BrdU ELISA was carried out according to the 
manufacturer’s instructions (Millipore). Absorbance of each plate was read at 450nm, and 
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this optical density reading was proportional to the amount of BrdU incorporation. 
Experiments were repeated three independent times on SMCs between passage 2 and 5. A 
Student’s T test was used to determine statistical significance, with p<0.05 considered 
significant.   
 
Quantitative Gene Expression 
 Total RNA was isolated and QPCR was performed as described in Chapter II. Data 
are represented as mean ± S.D., and Student’s T tests were used to determine statistical 
significance, with p<0.05 considered significant.  
 
Results 
Histologic features of ACTA2 TAAD 
 Initially we examined the histology of the ascending aorta in patients with ACTA2 
mutations who underwent aortic surgical repair. We had access to nine aortas from patients 
with the following mutations: R258H, Y135H, R118Q, T353N, R149C, R185Q, and I250L 
(Table 2). Similar to the MYH11 aorta in Chapter II, we used Movat staining to visualize 
multiple components of the vascular wall. Movat staining of aortic tissue revealed features 
of typical medial degeneration as indicated by the accumulation of proteoglycans (blue) and 
loss of elastic fibers (black) (Figure III-1A).  
57 
 
Figure III-1. Aortic pathology associated with ACTA2 mutations. (A) Movat and SM α-actin 
immunostaining of the media from control and ACTA2 mutant aortic tissues. Movat staining 
revealed typical features of medial degeneration in ACTA2 mutant tissue compared with 
control, including areas of SMC loss, proteoglycan accumulation (blue), lack of collagen 
accumulation (yellow) and fragmentation and loss of elastic fibers (black). SM α-actin 
immunostaining revealed areas of SMC hyperplasia and disarray compared with control. (B) 
Both H&E staining and SM α-actin immunostaining showed hyperplastic vessels were 
present in the adventitia in ACTA2 mutant aortic tissue but absent in control. The 
hyperplastic vessels were both enlarged in size and showed luminal narrowing, and in some 
A 
B 
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cases were completely occluded. SM α-actin immunostaining, along with von Willebrand 
factor staining (not shown) confirmed that these were blood vessels and that the hyperplasia 
was due to increased numbers of SMCs. Scale bars represent 100µm, and magnification for 
each panel is indicated. Reprinted by permission from Macmillan Publishers Ltd: [Nature 
Genetics] (34), copyright (2007). http://www.nature.com/ 
************************************************************************** 
We also examined the aortas to determine whether features similar to the MYH11 aorta were 
present, including disarray, focal areas with increased SMCs, and thickened vasa vasorum. 
Similar to MYH11 mutations, aortas from ACTA2 patients showed increased SMCs in focal 
areas, and we confirmed this by SM α-actin immunostaining (Figure III-1A). SMCs in the 
patients’ aortas also displayed areas of random orientation with respect to each other, similar 
to the disarray observed in the MYH11 aorta. The arteries in the vasa vasorum were also 
enlarged and thickened in ACTA2 patients compared with similar arteries in control aortas. 
Despite the enlargement, the vessels were stenotic, and in some cases were completely 
occluded. We stained for an endothelial specific marker (von Willebrand factor, not shown) 
and α-SM actin to confirm that these were blood vessels (Figure III-1B).  Immunostaining 
confirmed the identity of these structures as vessels, and also showed SMC hyperplasia. 
Data from two R149C mutant aortas and one T353N mutant aorta are shown, and these are 
representative of the enlarged vessels that were present in every ACTA2 mutant aorta where 
adventitial tissue was visible (the adventitial layer was completely missing in one tissue 
sample). We also used Movat-stained tissue samples to examine the integrity of the internal 
elastic lamina, and determine whether the proliferation in the vessels was confined to the 
media, to a neointimal layer, or a combination of both. Movat staining confirmed that the 
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internal elastic lamina of these vessels remained intact, and that vessel thickening was due to 
increased SMCs in the medial layer, rather than neointimal formation (not shown).  
 
SMC proliferation and occlusion in other arteries 
 During the course of our study, coronary artery and/or cardiac tissue from three 
individuals with ACTA2 mutations became available for pathologic examination (Table 2). 
Coronary artery tissue was obtained from a 28 year old male of Northern European descent 
heterozygous for an R118Q mutation who died from an acute aortic dissection. He did not 
have any known risk factors for cardiovascular disease or any diagnosis of CAD prior to 
death. Initial H&E staining showed 70% narrowing of the vessel due to an atherosclerotic 
lesion combined with increased cellularity in both the medial and intimal layers of the 
vessel. We used a Movat stain to determine which ECM components were increased in the 
vessel wall, and immunostained with SM α-actin to confirm that the increased cellularity 
was due to increased SMCs. We observed that the lesion in this individual was due to an 
accumulation mainly of cells rather than lipids, in contrast to typical atherosclerotic plaques. 
SM α-actin immunostaining confirmed that the accumulated cells were SMCs (Figure III-
2A).  
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Figure III-2. ACTA2 mutations are associated with SMC hyperplasia and SMC proliferation 
in culture. (A) Coronary artery tissue from a 28-year-old male heterozygous for an R118Q 
ACTA2 mutation showed 70% narrowing of the vessel, and this was due to a fibrocellular 
atherosclerotic plaque. Movat staining showed that this lesion was due mainly to 
accumulation of cells, and SM α-actin staining confirmed that these were SMCs. Scale bars 
represent 1.0mm in the top two panels (magnification 40x) and 200µm in the bottom two 
panels  (magnification 200x). (B) Epicardial arteries from two individuals heterozygous for 
ACTA2 mutations showed abnormal thickening. H&E, Movat, and SM α-actin staining are 
shown. The first individual (TAA441:III:6) had an R118Q mutation, and the second 
individual (TAA015:III:1) had an R292G mutation. (C) Cell proliferation assays showed 
that SMCs explanted from patients heterozygous for ACTA2 mutations (n = 2) proliferated 
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significantly more rapidly than matched control SMCs (n = 2), as quantified by ELISAs for 
BrdU incorporation. Error bars represent S.E.M. and p-value is indicated. Reprinted from 
(83), with permission from Elsevier.  
************************************************************************* 
Cardiac tissue was obtained from two patients, neither of whom were at high risk for CAD. 
The first sample was from a male of Northern European descent heterozygous for an R118Q 
mutation, who first had an acute aortic dissection at age 50, diagnosed with CAD at age 54, 
and died at age 59 after having a chronic aortic dissection surgically repaired. Pathologic 
examination of the tissue showed abnormal thickening of epicardial arteries. We used SM α-
actin and MOVAT staining to confirm that this thickening was due to SMC accumulation in 
the medial layer. The second sample was from a 53 year old Northern European female 
heterozygous for an R292G mutation, who died of unknown causes. Similar to the first 
tissue sample, abnormal thickening of epicardial arteries was found and noted at autopsy 
(Figure III-2B). Together, these data support the idea that pathologic changes due to 
ACTA2 mutations are not just confined to the aorta but are present in multiple vascular beds, 
including coronary arteries.  
 
SM α-actin expression, polymerization, and localization 
 Based on predicted structural alterations due to ACTA2 mutations, we hypothesized 
that SM α-actin filament formation would be impaired. To test this hypothesis, we 
immunolabeled SMCs explanted from ACTA2 patients and matched controls with both SM 
α-actin and phalloidin, which binds to all polymerized actin within the cell. Filaments in 
control SMCs extended across the cell body and colocalized with total actin filaments within 
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the cell. ACTA2 patients also showed filaments composed of other actin isoforms, but little 
to no SM α-actin-containing filaments. These data indicate that ACTA2 mutations result in a 
decrease in formation and/or stability of SM α-actin filaments (Figure III-3).  
 
Figure III-3. SM α-actin filament disruption due to ACTA2 mutations. Analysis of actin 
stress fibers in SMCs explanted from control (top row) and ACTA2 mutant aortas (bottom 
two rows). The left panels show phalloidin staining of total filamentous actin (red), the 
middle panels show SM α-actin (green), and the right panels show a merged image. SM α-
actin filaments were greatly reduced in ACTA2 mutant SMCs. Double labeling of the SMCs 
for total actin filaments showed that filamentous actin and SM α-actin were colocalized in 
 All filamentous actin         SM α-actin                  Merged, DAPI 
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the control SMCs. Little to no colocalization was observed in the ACTA2 mutant SMCs. 
Scale bars represent 40µm; magnification = 400x. Reprinted by permission from Macmillan 
Publishers Ltd: [Nature Genetics] (34), copyright (2007). http://www.nature.com/ 
************************************************************************** 
Interestingly, in the two samples available for study, actin filaments were disrupted to 
differing degrees. In SMCs heterozygous for an R118Q mutation, actin accumulated in the 
perinuclear region of the cell, and little to no filament assembly was observed. A T353N 
mutation resulted in formation of rodlike structures at the cell periphery. However, SM α-
actin filament formation was still greatly impaired, and filaments did not extend across the 
cell as in the controls (Figure III-3). Explanted SMCs from a third individual, heterozygous 
for an I250L mutation in ACTA2, showed too little ACTA2 expression initially to adequately 
analyze by immunofluorescence. We treated SMCs from this patient and from matched 
controls with TGF-β1, since it is a well known and potent stimulator of SMC differentiation. 
Expression of ACTA2 was increased upon TGF-β1 treatment; however, no SM α-actin 
filament formation was observed in these cells, and actin was accumulated mainly in the 
perinuclear region (Figure III-4). Findings in this patient were similar to the R118Q mutant 
SMCs in Figure III-3.   
 
Filamentous actin α-SM actin Merge, nuclei 
control 
ACTA2 
I250L 
64 
Figure III-4. SM α-actin expression in TGF-β1 treated ACTA2 SMCs. Since SMCs from a 
patient heterozygous for an ACTA2 I250L mutation expressed very low levels of SM α-
actin, these SMCs and matched controls were treated with 5 ng/mL TGF-β1. The left panels 
show phalloidin staining of total filamentous actin (red), the middle panels show SM α-actin 
(green), and the right panels show a merged image. 72 hours post TGF-β1 treatment, SM α-
actin expression was increased but failed to form filaments (green). In contrast, the SM α-
actin in controls formed filaments that colocalized with total actin in the cells.  
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Increased proliferation of ACTA2 mutant SMCs 
 Since multiple vessels from ACTA2 patients showed focal areas of SMC hyperplasia, 
we hypothesized that this was due to an increase in SMC proliferation within the vascular 
wall. We used BrdU incorporation assays to quantify DNA synthesis and determine whether 
explanted SMCs from these individuals proliferate more rapidly in vitro. We found that 
proliferation, as assessed by BrdU incorporation, was significantly increased in SMCs 
explanted from patients with heterozygous ACTA2 mutations (n=2) compared with age and 
gender matched controls (n=2) (Figure III-2C). These data are consistent with the 
histologic data, both from aortic tissues and from coronary and epicardial arteries from 
affected individuals, and indicated that ACTA2 mutations are associated with a proliferative 
vascular pathology, similar to MYH11 mutations. These data are also consistent with 
histologic findings in the MYH11 patient.  
 
Increased IGF-1 but not TGF-β1 or PDGF gene expression and immunostaining 
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 Due to the similar proliferative pathology in tissues and SMCs from both MYH11 
and ACTA2 patients, we hypothesized that IGF-1 would also be increased in ACTA2 mutant 
tissues and SMCs similar to MYH11 tissues and SMCs. IGF-1 transcript levels were 
significantly increased in two out of three SMC samples. The increase in IGF-1 was slightly 
variable, however, since a third SMC sample also displayed a slight increase in IGF-1 gene 
expression but this increase was not statistically significant (Figure III-5A).  
 
Figure III-5. IGF-1 expression is increased in ACTA2 SMCs and tissues. 
(A) IGF-1 gene expression is increased in ACTA2 mutant SMCs compared with matched 
controls, and increases in two out of three of these samples were statistically significant. 
Data are normalized to GAPDH. Experiments were performed in triplicate (control n=2; 
ACTA2 patient n=1 for each separate mutation). Labels indicate the specific ACTA2 
missense mutations, and error bars represent ± S.D. *p<0.05. (B) IGF-1 protein expression 
in aortic media (B, top two panels) and adventitia (B, bottom two panels) is increased in 
patients heterozygous for ACTA2 mutations. Immunostaining of IGF-1 in aortic tissues 
produced variable results overall, but was consistently increased in patients with R149C 
mutations.  
************************************************************************* 
A B 
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We also performed immunostaining using an IGF-1 antibody to determine whether IGF-1 
protein expression in the aortic tissue was increased. Similar to findings in our QPCR 
analysis, we observed increased immunoreactivity to IGF-1 in some but not all ACTA2 
aortas. Despite some variability among samples, however, IGF-1 immunostaining was 
consistently more intense in the aortas of patients heterozygous for R149C mutations and 
was present in both the aortic media and in the hyperplastic vasa vasorum in these tissues 
(Figure III-5B).  
 
Discussion 
 In Chapter II we described a novel proliferative pathology due to MYH11 mutations, 
and we hypothesized that additional mutations in SMC-specific contractile genes would both 
disrupt the contractile filament structure within the cell and lead to a vascular pathology 
similar to what we observed in the MYH11 aortic tissue. Consistent with our hypothesis, 
heterozygous missense mutations in ACTA2 led to disruption of SM α-actin filament 
formation in explanted SMCs, compared with controls. These data were also consistent with 
structural predictions based on the locations of the various mutations within ACTA2. In 
addition to disruption of SM α-actin filaments, ACTA2 aortas displayed a vascular pathology 
similar to the MYH11 patient, with focal areas of increased SMC hyperplasia and disarray, 
in both the media and in the vasa vasorum. We also found increased proliferation of ACTA2 
mutant SMCs in vitro in static culture, compared with controls. These data suggest that a 
contractile defect in SMCs leads to increased proliferation even in the absence of 
mechanical stress, and further confirms our hypothesis that contractile mutations in ACTA2 
and MYH11 lead to a common proliferative pathology.  
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 The incidence of early-onset CAD and stroke in ACTA2 mutant individuals raised 
the question of whether this proliferative pathology was present in other vascular beds, 
contributing to occlusive disease. We had the opportunity to analyze two cardiac tissue 
samples and one coronary artery tissue sample from patients heterozygous for ACTA2 
mutations, and we observed similar patterns of SMC hyperplasia, abnormal vessel 
thickening, and luminal narrowing in all of these samples. These data indicate that the 
proliferative pathology is indeed present in other vascular beds in affected individuals, and 
suggest that inappropriate proliferation of SMCs may be involved in the premature CAD and 
stroke due to ACTA2 mutations. Thickening and luminal narrowing of small vessels within 
the heart has previously been reported in cases of hypertension(137;138). 
 In addition proliferative pathology similar to MYH11, ACTA2 patients’ SMCs and 
tissues displayed increased IGF-1 gene and protein expression. As previously discussed, 
IGF-1 is a regulator of both SMC contractility and proliferation (107;108;108;109). IGF-1 is 
also upregulated in response to vascular injury (110-113). All of these studies suggest that 
the observed increase in IGF-1 may be contributing to the hyperplasia in ACTA2 mutant 
aortas. IGF-1 expression in some of the aortic tissues was variable, however. This variability 
may be due either to the specific mutation in ACTA2 or due to the unavoidable fact that 
tissue samples were collected at various stages of disease progression. Individuals 
heterozygous for R149C mutations consistently had higher levels of IGF-1 in aortic tissue 
than individuals with other mutations. Unfortunately, explanted SMCs from R149C mutant 
individuals were not available for study. Further experiments are necessary to determine 
whether IGF-1 is driving SMC proliferation, particularly in the patients’ samples with the 
highest levels of IGF-1 expression.  
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  One distinct advantage of this study is the availability of clinical data, which enabled 
correlations of the in vitro cellular phenotype to be made with the clinical presentation of 
disease. Pathologic analysis of blood vessels from ACTA2 mutant individuals suggested that 
vessel occlusion also played an important role in the disease process, and this finding 
correlated with the early onset CAD and stroke present in families carrying ACTA2 
mutations. Conversely, particularly in the case of livedo reticularis (LR), the clinical 
findings were able to inform the direction of research. In the family originally used to map 
and identify the first ACTA2 mutations, LR was a near-100% predictor of which individuals 
carried the mutant allele(34). The presence of LR, a known vascular occlusive condition, 
also prompted further analysis of occlusive diseases in ACTA2 mutant individuals and 
families.  
 Similar to the experiments using MYH11 SMCs and tissues, this study was limited 
by sample size and the availability of aortic tissues and explanted SMCs. Development of 
specific model systems for studying the cellular effects of ACTA2 mutations will allow for a 
better assessment of the in vitro cell proliferation and the specific molecular mechanisms 
driving the proliferation, and should be particularly useful in elucidating the role of IGF-1 in 
this process.  
 Our data from this study support both a decrease in SMC contractile function and an 
increase in proliferation due to ACTA2 mutations. SM α-actin filaments were disrupted in 
mutant SMCs, providing evidence that the mutations lead to disruption in SMC structure. 
Analyses of ACTA1 and ACTC mutations support the idea that missense mutations 
disrupting formation of actin filaments also lead to decreased contractility (139;140). Study 
of Acta2-/- mice shows that total loss of Acta2 decreases SMC contractility; the 
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development of transgenic and knock-in mouse models will aid in determining whether 
aortic contractility is altered due to mutation of Acta2 (117). Therefore, although the 
evidence is indirect rather than a direct measurement of contractile function, our results 
indicate a probable loss of SMC contractile function. Both the SMC hyperplasia in multiple 
vascular beds and the increased SMC proliferation in vitro support a gain of proliferative 
function due to ACTA2 mutations.  
 Individuals with early onset CAD or stroke in ACTA2 families lacked any of the 
major risk factors for cardiovascular disease, including hypercholesterolemia, severe and 
uncontrolled hypertension, or diabetes. These clinical data, along with the SMC 
accumulation in vivo within blood vessels in multiple vascular beds, along with the 
increased SMC proliferation in vitro, suggest that single missense mutations are capable of 
triggering a proliferative response leading to vessel stenosis and occlusion. This represents a 
novel pathway for development of occlusive vascular disease development due to a genetic 
defect. Further, the increase in IGF-1 and the established roles of IGF-1 in SMCs suggest 
that IGF-1 may be a key factor in driving proliferation and vessel occlusion. However, the 
specific role of IGF-1, as well as the mechanism(s) driving increased IGF-1 expression in 
the mutant tissues and SMCs, remain unknown.  
 In conclusion, ACTA2 mutations lead to disruptions in SM α-actin filament 
assembly, increased SMC proliferation, and increased IGF-1 expression. Future studies will 
focus on 1) developing a model system to overcome the difficulties with small sample size, 
2) elucidating the specific roles that IGF-1 plays in driving proliferation in ACTA2 SMCs, 
and 3) determining whether the increase in proliferation can be prevented, to delay the 
progression of disease in affected individuals.  
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CHAPTER IV 
ESTABLISHMENT AND CHARACTERIZATION OF A MODEL SYSTEM FOR 
DETERMINING MAJOR PATHWAYS DRIVING PROLIFERATION 
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Background 
 Myofibroblasts are cells with biochemical and morphologic features of both 
fibroblasts and SMCs and can arise from multiple cell types in numerous different organs 
(141). The complex regulation of this transition is complex but has been studied extensively. 
One of the hallmarks of myofibroblast differentiation is the expression of SM α-actin, but 
myofibroblasts also express multiple other SMC-specific contractile genes (142). Many 
different factors are capable of inducing myofibroblast differentiation in vitro and in vivo. In 
vitro, mechanical force due to stretching, composition and rigidity of the substrate can 
induce myofibroblast differentiation (143-145). Chemical modulators including TGF-β1 and 
heparin can also induce differentiation (141;146). Antimitotic agents have also been found 
to increase SM α-actin production (147). Cell density has also been shown to modulate the 
effects of various treatments and external forces on myofibroblast differentiation, and cells 
plated at low density gain a myofibroblast phenotype upon reaching confluence (148). In 
vivo, latent TGF-β1 is released from its inactive form in the extracellular matrix after 
mechanical stretch or injury, driving differentiation of myofibroblasts, which aid in wound 
healing. It is not completely known whether the disappearance of myofibroblasts is due to 
de-differentiation back into fibroblasts, apoptosis, or a combination of both (144;149).  
 Early events in myofibroblast differentiation involve TGF-β1/Smad signaling. TGF-
β1 binds to type II TGF-β receptors, which form heterotetramers with type I receptors, and 
are phosphorylated following TGF-β1 binding. Following receptor internalization, Smad 
anchor for receptor activation (SARA) aids in recruiting Smad2 and Smad3 to the receptor 
(150). Smad2 and Smad3 are phosphorylated, and the activated Smad2/3 complex 
translocates to the nucleus and activates transcriptional targets, including SM α-actin, 
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through a TGF-β control element (TCE) in the ACTA2 promoter (151). TGF-β1 also induces 
the expression of integrins and ECM, including fibronectin and collagen, driving 
autophosphorylation of FAK and subsequent activation of FAK signaling (152).  
 Later signaling events leading to SM α-actin protein accumulation within the cell are 
dependent on cell adhesion, ECM production, and signaling through FAK. Expression of the 
ED-A splice variant of fibronectin is required for TGF-β1-induced myofibroblast 
differentiation (153). Since maintenance of the myofibroblast phenotype is dependent on a 
stiff ECM, the sustained expression of SM α-actin may be dependent on cell adhesion-
dependent FAK signaling. In one study, a correlation was found between SM-α-actin levels 
and both autophosphorylated and total FAK (152). In contrast, another group reported that 
myofibroblast differentiation was enhanced in FAK-/- mouse embryonic fibroblasts (MEFs), 
suggesting that at least in MEF cells, TGF-β1 is capable of activating additional pathways to 
compensate for the loss of FAK in promoting SM α-actin expression (154). Together, these 
studies show that myofibroblast differentiation is adhesion-dependent and is regulated by 
FAK, but that other pathways are involved as well. Studies in 10 T1/2 cells have shown that 
the PI3K/Akt pathway is involved in transformation of these cells to SMCs upon treatment 
with TGF-β1 (155).  
 Differentiated myofibroblasts possess several distinct advantages as a model system 
for studying the cellular effects of ACTA2 mutations: 1) samples could more readily be 
obtained from affected individuals as well as normal controls, 2) samples heterozygous for a 
wider range of ACTA2 mutations could be tested, and 3) dermal fibroblasts exhibit 
phenotypic plasticity in certain culture conditions and can be induced to differentiate into 
myofibroblasts that synthesize SMC-specific contractile proteins.  
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 Although preliminary data suggested that both ACTA2 and MYH11 mutations lead to 
increased SMC proliferation, we chose to focus on ACTA2 mutations since they represent a 
larger percentage of all familial TAAD. Insight gained from these studies should be 
applicable to TAAD caused by mutations in other contractile proteins as well. The goals of 
this study are to 1) establish myofibroblasts as a model system for studying ACTA2 
mutations, 2) utilize this model system to confirm an increase in IGF-1 in a larger sample of 
patients with ACTA2 mutations, and 3) determine the role of IGF-1 in cell proliferation due 
to ACTA2 mutations. The importance of IGF-1 in SMC differentiation, as well as the ability 
of IGF-1 to induce SMC proliferation, has been discussed previously (see Discussion, 
Chapter II). Also, an extensive body of literature suggests that myofibroblasts expressing 
SM α-actin are an adequate model system for our study. We hypothesize that ACTA2 mutant 
myofibroblasts proliferate more rapidly than controls, similar to the cultured SMCs, and 
that the proliferation occurs in an IGF-1 dependent manner.  
 
Materials and Methods 
Dermal fibroblast explant and culture 
 All studies involving human subjects were approved by the institutional review 
board at the University of Texas Health Science Center at Houston (UTHSCH), and 
informed consent was obtained from all study participants. Dermal fibroblasts were 
explanted from 9 patients heterozygous for ACTA2 mutations and from 10 controls matched 
for age and gender, using a previously established protocol. None of the controls had a 
known history of vascular disease. All samples used for study are listed in Table 3 of 
Chapter III. Small biopsies of dermal tissue were obtained from the forearm. Tissue was 
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briefly washed in 70% ethanol, PBS, and DMEM, and epidermal and fatty layers of tissue 
were removed. Tissues were minced and placed in 60mm dishes. A glass coverslip was 
placed over the tissue pieces, and 3mL DMEM containing 10% FBS was added to the dish, 
and media was changed twice a week. Cells were allowed to migrate out of the tissue, and 
were trypsinized and seeded into flasks once multiple areas of confluence were apparent 
under the coverslips. Fibroblasts were cultured in DMEM containing 10% FBS, and were 
used for experiments at passage 2 through 5.  
 
Myofibroblast protocol 1: Low density/high density plating 
 Low density and high density plating of dermal fibroblasts was done using a 
published protocol, with minor modifications (148). Dermal fibroblasts were grown to 
confluence in T75 flasks, and were plated at either 5 or 500 cells/mm2 in DMEM containing 
10% FBS. Culture medium was replaced every three to four days. Upon reaching 
confluency, cells were serum-starved for 24 hours and harvested for RNA and protein 
analysis. Cells plated at high density reached confluence within 1 day or less, while cells 
plated at low density did not reach confluence for nearly 2 weeks, and this time frame varied 
somewhat among samples.  
 
Myofibroblast protocol 2: TGF-β1 treatment 
 Dermal fibroblasts cultured in T75 flasks were allowed to remain at confluency for 
4-5 days prior to each experiment. Cells were plated in duplicate at 80-100% confluency in a 
final volume of 2mL into 60-mm dishes, to allow for both RNA and protein analysis. Cells 
were allowed to settle overnight (20-24 hours). Culture medium was removed, and 2 mL 
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DMEM containing 0.2% FBS was added to each dish. After 24 hours of serum starvation, 
two plates were harvested for RNA and protein analysis. This was time zero, and was used 
as an untreated control. 2mL fresh DMEM containing 0.2% FBS ± TGF-β1 (10ng/mL; R&D 
Systems, Inc.) was added to the remaining plates. A 10 ng/mL dose was used because others 
had shown that it was an optimal dose for differentiating primary fibroblast cultures (149). 
For initial analysis, cells were washed 1x in PBS and harvested 24, 48, and 72 hours post 
treatment ± TGF-β1, to determine the best time point for analyzing SM α-actin protein 
(Figure IV-1A). For all subsequent experiments, cells were analyzed 72 hours post 
treatment ± TGF-β1. 
 
Figure IV-1. Myofibroblast time-course experiment. (A) Control myofibroblasts (n=4) were 
differentiated from dermal fibroblasts through TGF-β1 treatment, and a time course 
experiment was performed to determine the best timepoint for harvesting myofibroblasts for 
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our study. Fibroblasts were plated at confluence. 20-24 hours after plating, fibroblasts were 
serum-starved for 24 hours. Quiescent fibroblasts were either harvested at a zero-hour 
timepoint or treated ± TGF-β1 and incubated for an additional 24, 48, or 72 hours. (B) 
ACTA2 transcript levels (left panel) and SM α-actin protein expression (right panel) were 
increased upon TGF- β1 stimulation. Transcript levels were normalized to GAPDH, and the 
fold change relative to serum starved controls is shown. ACTA2 transcript levels were 
slightly greater after 48 hours than 72 hours; however, the greatest amount of SM α-actin 
protein was expressed at 72 hours, consistent with previously published results. 
Representative immunoblots from three experiments are shown. Densitometry is a 
composite from different fibroblast strains (right panel). Data are shown ± S.D. * p=0.05, 
**p<0.01.  
************************************************************************** 
Protein isolation and immunoblotting 
 Protein was harvested in RIPA buffer containing 50 mM Tris-HCl pH 7.4, 1% NP-
40, 0.25% Na-deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM PMSF, 30µL/mL protease 
inhibitor cocktail (Sigma), and phosphatase inhibitors (10 mM NaF and 1 mM Na3VO4). 
Samples were incubated at 4ºC for 30 minutes and vortexed 3x periodically throughout the 
incubation period, followed by centrifugation at 13,000 rpm for 30 minutes. Pellets were 
discarded, and supernatant was quantified using a Bradford assay. Equal amounts (10µg) of 
protein were boiled for 5 minutes in loading buffer, and loaded onto 4-20% acrylamide gels 
(Bio-Rad). Protein was transferred to PVDF membranes and immunoblotted using standard 
techniques. Briefly, membranes were blocked in 5% nonfat dry milk in TBS-T for 1 hour, 
followed by primary antibody for either 1-2 hours at room temperature, or overnight at 4ºC. 
77 
Secondary antibodies were used at a concentration of 1:5000 for one hour at room 
temperature. Antibodies used are listed in Table 1 of Chapter II.   
 
RNA isolation and quantitative gene expression analysis 
 RNA isolation and QPCR analysis were performed as previously described. 
 
Immunofluorescence 
 Dermal fibroblasts were seeded onto 22mm glass coverslips at a density of 5,000 
cells per coverslip and allowed to attach overnight. Myofibroblast differentiation was carried 
out as described. 72 hours post TGF-β1 treatment, cells were fixed in 4% paraformaldehyde, 
and immunofluorescent labeling was carried out as previously described for SMCs. Table 1 
lists the antibodies and concentrations used.  
 
Cell proliferation assays 
 Dermal fibroblasts were seeded in triplicate at a density of 20,000 per well, and were 
allowed to attach overnight before serum-starving in DMEM containing 0.2% FBS. 24 hours 
after serum deprivation, cells were treated ± TGF-β1 (10 ng/mL) and allowed to incubate for 
72 hours, followed by incubation with BrdU reagent for an additional 24 hours. Cells were 
fixed, and BrdU ELISAs were carried out according to the manufacturer’s instructions. 
Assays were repeated three separate times (ACTA2 patients, n=9; controls, n=10). Statistical 
significance was determined using Student’s t-tests.  
 For the IGF-1 receptor inhibitor and neutralizing antibody assays, fibroblasts were 
plated in triplicate at 10,000 cells per well, serum-starved, and treated with TGF-β1 (10 
78 
ng/mL) as described above. 72 hours post TGF-β1 treatment, cells were pre-treated for 30 
minutes ± two different doses (0.1 µM and 1 µM) of PQIP (cis-3-[3-(4-methyl-piperazin-l-
yl)-cyclobutyl]-1-(2-phenyl-quinolin-7-yl)-imidazo[1,5-a]pyrazin-8-ylamine), a specific 
IGF-1R inhibitor (OSI Pharmaceuticals, Inc.) before BrdU reagent was added (156). Cells 
were also treated ± 200 nM IGF-1 as a positive control for inhibitor specificity. Cells were 
incubated with BrdU reagent for 24 hours and fixed, and BrdU incorporation was quantified 
through ELISA, according to the manufacturer’s instructions (Millipore, Billerica, MA). 
Data are representative of three independent experiments. For the neutralizing antibody 
assay, cells were plated in duplicate and treated ± α-IR3, an IGF-1R neutralizing antibody (2 
µg/mL; Abcam) instead of PQIP. This concentration was chosen because concentrations of 1 
µg/mL and 2.5 µg/mL have been shown inhibit proliferation in MCF7 cells and in metastatic 
non-small cell lung cancer cells, respectively (157;158). Student’s t-tests were used to 
determine statistical significance.  
 
Analysis of IGF-1 secretion 
To quantify IGF-1 secretion by ACTA2 mutant and control cells, myofibroblasts, an 
IGF-1 ELISA (R&D Systems, Inc., Minneapolis, MN) was used. Cell culture supernatant 
from 9 ACTA2 myofibroblast and 10 control myofibroblast samples were assayed, and the 
IGF-1 ELISA was performed according to the manufacturer’s instructions. To better 
concentrate the IGF-1 in the tissue culture supernatant, samples were concentrated using 
Amicon Ultra centrifuge tubes (Millipore, Billerica, MA).  
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Results 
Establishment of a myofibroblast model system 
 To determine the best method for myofibroblast differentiation, we tested two 
different methods that were previously described in the literature. The first method involved 
plating fibroblasts at low density and allowing them to grow to confluence, and the second 
method involved treating confluent, serum-starved fibroblasts with TGF-β1 (148;149). 
Plating fibroblasts at high vs. low density yielded variable and inconsistent results (data not 
shown). Another disadvantage is that this method was time-consuming. Low density plated 
cells took several weeks to reach confluency, and often did not survive well from being 
plated so sparsely. In contrast, TGF-β1 treatment yielded far better and more consistent 
results. One study showed that TGF-β1 treatment resulted in significantly increased SM α-
actin gene and protein expression as early as 24 hours, and another study showed that the 
optimal amount of incubation time after TGF-β1 stimulation was 72 hours (149;151). We 
tested several different timepoints to confirm the optimal incubation time in our fibroblast 
system. SM α-actin mRNA was increased significantly 24 hours after TGF-β1 treatment, 
and remained elevated at 48 and 72 hours (p<0.01). Immunoblot analysis showed that SM α-
actin protein expression was increased by 48 hours, with the greatest expression most 
consistently at 72 hours (p<0.05; Figure IV-1B). A representative immunoblot from one out 
of three independent controls is shown. Therefore, a 72-hour timepoint was used for the 
remainder of experiments.  
 Dermal fibroblasts express SM α-actin in addition to other SMC contractile proteins 
upon differentiation into myofibroblasts. Therefore we hypothesized that the myofibroblasts 
would be a good model system for determining whether inducing SM α-actin expression had 
80 
a proliferative effect on patients’ myofibroblasts. Assays for SM α-actin expression, actin 
polymerization, and cell proliferation showed that myofibroblasts displayed similar 
characteristics to SMCs and are a valid model system. Treatment of fibroblasts explanted 
from controls (n=10) and from patients heterozygous for ACTA2 mutations (n=9) all showed 
increased SM α-actin mRNA and protein expression at 72 hours following TGF-β1 
treatment, consistent with published results (Figure IV-2A,B) (149).  
 
Figure IV-2. SM α-actin expression in ACTA2 mutant and control myofibroblasts. Both 
ACTA2 mutant and control dermal fibroblasts significantly increase SM α-actin transcript 
levels (A) and protein expression (B) 72 hours post TGF-β1 treatment (10ng/mL). Samples 
with less of an increase in ACTA2 gene expression also displayed less SM α-actin protein 
expression following TGF-β1 treatment. Gene and protein expression levels varied, with the 
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most notable differences between R149 and R258 mutations. Error bars represent ± S.D. 
QPCR data are normalized to GAPDH and are a composite of three experiments, and 
representative immunoblots are shown. *p<0.05, **p<0.01.  
************************************************************************** 
Interestingly, the level of ACTA2 mRNA expression varied depending on the mutation, even 
though all samples displayed a significant increase in mRNA expression upon TGF-β1 
stimulation. The most marked difference was between R149C and R258H mutant samples. 
SM α-actin protein expression was increased in all samples that were studied, and followed 
a trend similar to that observed in mRNA levels.  
 Next, we used two different methods to determine whether SM α-actin filament 
structure was disrupted in ACTA2 mutant myofibroblasts compared with controls: 
immunofluorescent labeling of SM α-actin, and an ultracentrifugation assay to separate 
polymerized vs. unpolymerized actin, followed by immunoblotting for SM α-actin. 
Immunofluorescent staining showed that SM α-actin filaments were disrupted in patients’ 
myofibroblasts compared with controls (Figure IV-3A).  
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Figure IV-3. SM α-actin polymerization is disrupted in ACTA2 mutant myofibroblasts. 
Immunofluorescent labeling of total actin filaments (red) and SM α-actin (green) showed 
normal total actin as well as α-actin filaments in control myofibroblasts, and these filaments 
colocalized within the cell. In contrast, patients’ myofibroblasts lacked SM α-actin 
filaments, and α-actin localized mainly in the perinuclear region, similar to results obtained 
in ACTA2 explanted SMCs.  
************************************************************************** 
 As a final step both in testing myofibroblasts as a model system and in confirming 
that ACTA2 mutations lead to increased proliferation, we quantified the amount of DNA 
synthesis in ACTA2 mutant vs. control myofibroblasts. 72 hours post TGF-β1 treatment, we 
added BrdU reagent to the myofibroblasts and allowed cells to incubate an additional 24 
hours. ACTA2 mutant myofibroblasts showed significantly faster proliferation, as assessed 
control 
ACTA2 
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ACTA2 
R258H 
Filamentous actin α-SM actin Merge, nuclei 
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by BrdU incorporation, in culture than age and gender matched controls (Figure IV-4, 
Table 3).  
 
Figure IV-4. Increased proliferation in ACTA2 mutant myofibroblasts. (A) ACTA2 mutant 
myofibroblasts (n=9) proliferated significantly more rapidly than controls (n=10) 72 hours 
post treatment with TGF-β1. (B,C) Some variability was observed in the amount of 
proliferation of R149C vs. R258H myofibroblasts. R149C mutant cells (n=3) proliferated 
nearly twice as rapidly as matched controls, while R258H mutant cells (n=2) showed only a 
marginal increase in proliferation. Data shown are a composite of three experiments, and 
error bars represent ± S.E.M. *p<0.05, **p<0.01, ns = not significant.  
************************************************************************* 
These data further confirm our hypothesis that disruption in ACTA2 causes an increase in 
proliferation. These data also indicate that myofibroblasts are a suitable model for studying 
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the mechanisms driving increased proliferation due to ACTA2 mutations. However, similar 
to the variability in SM α-actin expression, the amount of cell proliferation also appeared to 
be dependent on the mutation. The largest difference was observed between myofibroblasts 
harboring an R149C vs. R258H mutations (Figure IV-2, Figure IV-4). While R149C 
mutant myofibroblasts proliferated nearly twice as rapidly as controls, R258H 
myofibroblasts displayed only a marginal increase in proliferation that failed to reach 
statistical significance.   
 
Increased IGF-1 gene expression but not systemic IGF-1 production 
 We quantified IGF-1 gene expression in myofibroblasts to determine whether 1) 
IGF-1 gene expression was increased similar to ACTA2 mutant SMCs, 2) whether sample-
to-sample variations in the levels of IGF-1 expressions existed, and 3) whether TGF-β1 
induced myofibroblast differentiation would be suitable for elucidating the role of IGF-1 in 
ACTA2 SMC proliferation. IGF-1 gene expression was significantly increased in ACTA2 
mutant myofibroblasts but not in controls upon TGF-β1 treatment. Similar to SM α-actin 
expression and proliferation, the increase in IGF-1 expression varies based on the mutation 
and cell strain. The R149C myofibroblasts expressed more IGF-1 than R258H 
myofibroblasts (Figure IV-5).  
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Figure IV-5. Increased IGF-1 gene expression in ACTA2 mutant myofibroblasts. 
IGF-1 gene expression was significantly increased 72 hours post TGF-β1 treatment in four 
out of six ACTA2 mutant myofibroblast samples tested (three out of four different ACTA2 
mutations) compared with controls (n=5). The amount of IGF-1 overexpression was variable 
in the patients, similar to ACTA2 gene expression results and appears somewhat proportional 
to ACTA2 expression levels seen in Figure IV-3a. Notably, a stark contrast between IGF-1 
expression in R149C vs. R258H mutant cells existed. The variable expression is similar to 
results obtained in explanted ACTA2 SMCs. Data are normalized to GAPDH mRNA, and 
error bars represent S.D. *p<0.05. 
************************************************************************** 
Since IGF-1 mRNA levels were increased, we made multiple attempts to quantify IGF-1 
secretion by the myofibroblasts in culture. However, ELISAs performed on tissue culture 
supernatant (R&D Systems, Inc.) failed to yield detectable levels of IGF-1, even after 
centrifugation to concentrate media samples, and we were unable to determine whether the 
increased IGF-1 mRNA corresponded with an increase in protein expression and secretion.  
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Partial inhibitory effect of IGF-1R neutralizing antibodies or IGF-1R blocker on 
proliferation 
 The goal of this study was both to establish a model cell system, and to utilize the 
model to study the pathways driving proliferation in ACTA2 mutant cells. IGF-1 transcript 
levels were increased in MYH11 SMCs, ACTA2 SMCs, and ACTA2 myofibroblasts, and 
IGF-1 immunoreactivity was increased in MYH11 and ACTA2 aortic tissues. Since IGF-1 
has known roles in promoting proliferation, we determined whether preventing IGF-1 
signaling through the IGF-1 receptor would prevent the observed increase in proliferation. 
To accomplish this, we used two different inhibitors: a small molecule inhibitor of IGF-1R 
(PQIP), and an IGF-1R neutralizing antibody (α-IR3). Previously published data using PQIP 
showed an IC50 within a nanomolar range, and that the IC50 for blocking cell proliferation in 
a number of cancer cell lines was between 0.023-0.6 µM (156). Based on these data, we 
used doses of 0.1 uM and 1 µM for our studies. PQIP blocked all IGF-1-induced 
proliferation in both control and ACTA2 mutant myofibroblasts; however, the patients’ 
myofibroblasts continued to proliferate significantly more rapidly than the control cells even 
after PQIP treatment (Figure IV-6A).  
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Figure IV-6. ACTA2 mutant myofibroblast proliferation in vitro is not dependent on IGF-1. 
(A) A specific IGF-1 receptor kinase inhibitor (PQIP; OSI Pharmaceuticals, Inc.) completely 
prevents IGF-1 induced proliferation; however, in patients’ cells, proliferation is still 
significantly greater than in controls after treatment with 1 µM PQIP, suggesting that 
increased proliferation in these cells in vitro is not IGF-1 dependent. IGF-1 + PQIP 
treatment served as a control to confirm inhibitor specificity. Data are representative of three 
independent experiments. Error bars represent mean ± S.E.M. *p<0.05. (B) Similar results 
were obtained using an IGF-1 receptor neutralizing antibody (α-IR3) at a concentration of 
2µg/mL. Error bars represent mean ± S.E.M. *p<0.05.  
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************************************************************************** 
Similar results were obtained using an IGF-1R neutralizing antibody at a dose similar to 
inhibitory doses used in two different cancer cell lines (Figure IV-6B). These data suggest 
that at least in vitro, factors other than (or in addition to) IGF-1 are driving proliferation in 
the ACTA2 mutant cells.  
 
Discussion 
 The goals of this study were to develop a model for studying ACTA2 mutations, and 
to use this model to determine whether the observed increase in proliferation is dependent 
on IGF-1. ACTA2 mutant myofibroblasts express SM α-actin, have disrupted α-actin 
filaments, increased proliferation, and increased IGF-1 expression compared with controls, 
similar to explanted SMCs. These data all suggest that myofibroblasts are a good model for 
studying the pathways leading to increased proliferation in the mutant SMCs.  
 Since IGF-1 is capable of driving both contractility and proliferation in SMCs, we 
hypothesized that proliferation in these cells is dependent on IGF-1, and utilized the 
myofibroblast model to address this question. However, the inability of the specific IGF-1 
receptor inhibitor PQIP, an IGF-1 receptor neutralizing antibody, and additionally an ERK 
inhibitor to completely block proliferation in these cells suggest that mechanisms other than 
IGF-1 are driving proliferation in vitro. These mechanisms are likely complex, involving 
input from multiple signaling pathways.  
 In addition to characterizing myofibroblasts as a model system and assessing 
whether IGF-1 is driving proliferation in this system, we made some unexpected 
observations, which may have clinical relevance. Some differences existed in SM α-actin 
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and IGF-1 expression as well as proliferation in the mutant myofibroblasts. Based on the 
consistency of the results from the controls, and the different clinical phenotypes observed 
associated with R149C vs. R258H mutations, we hypothesize that these differences may 
indicate slightly different disease mechanisms. R149C mutations are more frequently 
associated with premature CAD, while R258C/H mutations are more associated with 
premature stroke, along with Moyamoya disease. Some of the mutant myofibroblasts, 
particularly those heterozygous for R258H mutations, showed less of an increase in ACTA2 
upon TGF-β1 stimulation than other patients and controls, suggesting that either these 
particular cell strains do not produce as much SM α-actin in response to TGF-β1 
stimulation, or that some SM α-actin RNA and/or protein may be degraded. The same 
myofibroblast samples (R149C vs. R258H mutant samples) also showed distinct differences 
in proliferation after TGF-β1 treatment. Future studies will determine whether the 
differences in R149C and R258H cells are clinically relevant, or are merely due to inherent 
differences between primary fibroblast cell strains.  
 Myofibroblasts have proved useful as a model system, but they have several inherent 
disadvantages. One drawback is that even after TGF-β1 stimulation, these cells are not fully 
differentiated SMCs. Myofibroblasts express, but do not show SMC-specific splicing of, 
SMC terminal differentiation markers (159). Also, myofibroblasts and SMCs contract using 
different cellular mechanisms. Myofibroblasts contract mainly through Rho/ROCK 
activation and subsequent inhibition of myosin light chain phosphatase (144). This pathway 
leads to increased Ca2+ sensitization in SMCs, but contraction and maintenance of vascular 
tone are also regulated by Ca2+ influx via stretch-dependent ion channels and voltage 
dependent Ca2+ channels (160). Ca2+ binds to calmodulin and activates myosin light chain 
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kinase. Phosphorylated myosin light chain allows for myosin to interact with actin and 
generate contractile force (160). Also, contractile force generation is reversible in SMCs but 
irreversible in myofibroblasts (144). Therefore, while myofibroblasts may help provide 
insight into some cellular pathways, these cells may not be a good model system for 
studying SMC contractility directly. In addition, the use of myofibroblast strains from 
multiple individuals raises the possibility of genetic variability among patients and controls. 
Another shortcoming of both the myofibroblast model and the SMCs used in Chapters II and 
III is that all of these cells were grown in static culture, whereas SMCs in vivo are subjected 
to mechanical strain due to pressure from blood flow. Finally, in the current study, the TGF-
β1 treatment protocol created difficulties with accurately assessing IGF-1R activation. The 
time frames for IGF-1R activation after myofibroblast differentiation through TGF-β1, the 
length of the activation, and time of IGF-1 production are not known. Additionally, the 
mechanism by which a specific contractile defect causes upregulation of IGF-1 is still not 
known.  
 Despite these disadvantages, the myofibroblast model system still has some 
advantages. The system is inducible in that the expression of SMC contractile genes can be 
switched “on” and “off” based on a combination of the presence of TGF-β1 and the density 
at which the cells are plated (149), An inducible model is advantageous because it has the 
potential to reveal defects in the ability of SMCs to maintain a differentiated, contractile 
phenotype in response to external stimuli. Current data obtained using the myofibroblast 
model do not indicate that ACTA2 mutant SMCs have an impaired ability to maintain a 
differentiated SMC phenotype, as shown by their robust upregulation of SM α-actin mRNA 
and protein. However, this myofibroblast system is currently being utilized to show defects 
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in SMC differentiation caused by TGFBR2 and COL3A1 mutations (Inamoto S. et al, 
manuscript submitted; Dianna Milewicz, personal communication). 
 In conclusion, we have developed a myofibroblast model system that proved to be 
useful in confirming a proliferative phenotype in ACTA2 mutant cells. However, due to the 
inherent differences between myofibroblasts and SMCs, a SMC-specific model is needed for 
further study of the specific mechanisms driving proliferation. Since actin filaments are 
disrupted in both ACTA2 mutant SMCs and myofibroblasts, pathways that regulate both 
actin polymerization and cell proliferation are excellent candidate pathways. Future work 
will focus on 1) developing an SMC-specific cell culture model, 2) determining whether 
pathways with a dual role in regulating actin polymerization and contractility drive 
proliferation in this model and 3) confirming results in ACTA2 mutant SMCs. Additionally, 
once these studies are completed, a transgenic or knock-in mouse model of Acta2 mutations 
is needed to elucidate the specific role of increased proliferation in vivo. Although IGF-1 
does not appear to be driving proliferation in vitro in R149C mutant myofibroblasts, 
increased IGF-1 expression may still contribute to proliferation in vivo, and mouse models 
of vascular injury and/or IGF-1 overexpression support this idea (110-113). Transgenic 
mouse models with Acta2 mutations will be essential for addressing this question. These 
mice could either be crossed with mice that overexpress or underexpress IGF-1, or IGF-1R 
inhibitors could be used in vivo in these mice, to aid in determining whether IGF-1 drives 
proliferation and is ultimately involved in disease pathogenesis.  
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CHAPTER V 
IDENTIFICATION OF PROLIFERATIVE PATHWAYS ACTIVATED BY LOSS OR 
MUTATION OF ACTA2 
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Background 
 While myofibroblasts have some advantages and usefulness as a model system, these 
cells also possess a number of limitations that complicate the determination of proliferative 
mechanisms (see Discussion, Chapter IV). Based on the myofibroblast studies, we 
concluded that a SMC-specific model system is needed. In the absence of transgenic or 
knock-in mouse models of Acta2 mutations, we considered three different model cell lines 
or cell strains: transformed SMC lines transfected with vectors containing mutant ACTA2, 
similarly transfected primary SMCs, or Acta2-/- SMCs.  
 Based on all of the available information about other cell strains, we chose to utilize 
primary smooth muscle cells explanted from Acta2-/- mice as a model system. These cells 
have several distinct advantages. First, unlike the myofibroblasts, they are genetically 
uniform and should yield consistent results. Any differences between wildtype and Acta2-/- 
SMCs are less likely to be due to extraneous genetic factors. Second, they are primary SMCs 
rather than SMC lines that may have acquired other mutations or chromosomal alterations 
since undergoing transformation. Third, these cells provide an ideal model for studying a 
complete loss of SM α-actin filaments. Since α-actin filaments are disrupted in all of the 
mutant cells that were assessed, we hypothesize that a complete loss of SM α-actin should 
result in a similar phenotype and provide valuable insight into the mechanisms driving 
proliferation and vascular occlusive disease associated with ACTA2 mutations in humans. 
 Acta2-/- mice were generated by Dr. Robert Schwartz and colleagues in 2000 by 
inserting a vector containing the Acta2 gene with a Pol2neobpA cassette at the 
transcriptional start site into embryonic stem cells, disrupting transcription of the Acta2 
gene. Successfully targeted cells were injected into blastocysts of C57 mice to generate a 
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chimeric mouse, and offspring were bred and genotyped for the presence or absence of 
Acta2 (117). Major findings in the Acta2-/- mice included decreased contractility of isolated 
aortic ring segments, decreased systolic blood pressure, inability to increase blood flow in 
response to elevated body temperature, and impaired ability to raise blood pressure back to 
normal levels after infusion with sodium nitroprusside, a compound that lowers blood 
pressure. Acta2-/- mice showed a flattened appearance of elastic fibers in the aorta, which is 
also indicative of decreased contractility. However, these mice were viable and the vascular 
system developed normally. Other findings included increased mRNA and protein 
expression of skeletal α-actin, presumably a compensatory response due to the complete loss 
of SM α-actin. Endogenous skeletal α-actin overexpression, however, was unable to 
completely restore contractility in the Acta2-/- vessels (117). Additionally, electron 
microscopy revealed decreased formation of myosin thick filaments, providing evidence that 
disruption of one element of the contractile apparatus leads to disruption of other 
components as well (117).  
 In 2004, Zimmerman et al reported that Acta2-/- mice displayed decreased bladder 
contractility in vitro and in vivo. Although this finding was significant in vitro, it was not 
statistically significant in vivo, potentially because SM γ-actin is more abundant than SM α-
actin in the bladder. A third study showed that loss of Acta2 does not cause major 
morphologic changes in retinal structure, but increased permeability of the blood-retinal 
barrier, which resulted in decreased retinal function (161). A fourth study reported increased 
kidney myofibroblast proliferation in Acta2-/- mice, using a unilateral ureteral obstruction 
model of kidney injury (124). Acta2-/- mice showed increased fibrosis compared to wildtype 
post-injury, as well as increased myofibroblast proliferation and procollagen-1 expression 
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both in vitro and in vivo. These defects were rescued by transfection with an adenovirus 
containing wildtype Acta2, providing evidence that the proliferation as well as the increased 
injury response were due to an inability of the Acta2-/-  kidney myofibroblasts to produce 
smooth muscle α-actin (124). Additionally, FA proteins including phosphorylated FAK, 
total FAK, paxillin, and vinculin were increased in Acta2-/- myofibroblasts (124). The 
authors suggested that disruption of Acta2 leads to alterations in FAs, and that this 
disruption may play an important role in disease development in their model (124). 
However, the exact nature of the role of FAs in this disease process remains undefined.  
 From studies with the Acta2-/- mice, it is clear that both proliferation and SMC 
contractility are altered due to the complete loss of a contractile protein. Others have 
demonstrated that SM α-actin expression slows the growth of tumors and immortalized cell 
lines, providing support for our argument that loss of contractile filaments can result in 
either a loss or a gain of function depending on the location of the vascular bed (162;163). 
Additionally, SM α-actin has a p53 response element within the promoter region, and is a 
transcriptional target of p53 (147). We have shown that mutations that either disrupt or are 
predicted to disrupt Acta2 polymerization lead to an increase in SMC and myofibroblast 
proliferation, suggesting that total loss of Acta2 as well as deletion of Acta2 may drive 
proliferation via similar cellular mechanisms (83). Therefore, SMCs explanted from Acta2-/- 
mice should yield valuable insight into proliferative pathways in ACTA2 mutant SMCs.  
 As mentioned in the previous chapter, pathways and molecules that regulate both 
SMC contractility and proliferation are excellent candidates for our study. One such 
pathway is Rho/ROCK signaling. In SMCs, Rho is activated in response to contractile 
agonists including endothelin-1 and Ang II that activate G-protein coupled receptors (160). 
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Rho/ROCK signaling can also be activated in response to growth factor stimulation, 
mechanical stretch, or through cell-ECM interactions (164). Rho activates ROCK, which 
inactivates myosin phosphatase, allowing for myosin light chain to remain active 
(phosphorylated) and increasing the cell’s sensitivity to calcium (160). Rho also plays an 
essential role in driving actin polymerization by activating multiple effector proteins within 
the cell. Increased actin polymerization in turn drives the expression of SMC-specific 
markers including SM22, SM α-actin, SM myosin heavy chain, and calponin (165). In 
addition to its roles in actin polymerization and SMC-specific gene expression, multiple 
studies suggest that elevated Rho/ROCK signaling promotes SMC proliferation. Rho/ROCK 
signaling leads to reduced p27 levels through increased Skp2 production, as well as elevated 
cyclin D1 levels, resulting in cell cycle progression (166;167). Constitutively active Rho 
promoted BrdU incorporation into NIH3T3 cells (168). HMG CoA reductase inhibitors 
(statins) decreased the amount of Rho present at cell membranes and prevented Rho-induced 
reduction of p27 levels, thereby reducing SMC proliferation (169). Although one study 
reported that Rho activation did not induce SMC proliferation, this study was done on SMCs 
from saphenous veins (170). Others have shown that arteries and veins are structurally and 
functionally different, and that SMCs explanted from arteries vs. veins respond differently in 
vitro, which could account for the disparity in results obtained (171). Overall evidence 
suggests that Rho/ROCK activation is capable of driving SMC proliferation.  
 SRF-dependent regulation of SMC phenotypic switching may also contribute to the 
increase in proliferation, and a general overview of SMC phenotypic switching is provided 
in Chapter I. SRF acts as a molecular “switch” between contractile and growth-responsive 
gene expression in SMCs, and that this switching is regulated in part through actin 
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polymerization and nuclear localization of myocardin-related transcription factors (MRTFs) 
(172;173). SRF phosphorylation at Ser162 leads to inhibition of myogenic genes, while still 
allowing for expression of proliferative genes (174).  Experimental evidence from multiple 
sources shows that levels of unpolymerized actin (G-actin) within the cell control SRF 
activation through regulation of MRTFs (175). There are two main classes of SRF cofactors: 
MRTFs, which control muscle-specific differentiation, and TCFs that control growth factor 
responsive genes (175). When G-actin levels increase in the cell, MRTF-A is exported from 
the nucleus and binds to G-actin. MRTFs, which are normally found in the nucleus in 
differentiated SMCs, are localized in the cytoplasm in fibroblasts but translocate to the 
nucleus upon stimulation of RhoA-mediated actin polymerization (176). MRTFs and TCFs 
compete with each other for binding to SRF (177). Removal of MRTF from the nucleus 
increases the amount of SRF that binds to TCFs, allowing for greater smooth muscle cell 
proliferation and growth. Activation of TCF/SRF transcription complexes is also promoted 
by factors including mechanical stretch, vascular injury, and exogenous growth factor 
stimulation, leading to increased ERK activation (175). Thus, changes in actin 
polymerization coupled with vascular injury and/or the presence of excess growth factors 
could potentially lead to a switch between MRTF/SRF and TCF/SRF mediated transcription 
and subsequent proliferation.  
 Both Rho/ROCK and SRF mediated pathways are plausible candidates for driving 
proliferation in ACTA2 mutant SMCs due to decreased SM α-actin polymerization. 
However, this presents a potential dilemma in Acta2-/- SMCs, since there are no pools of 
unpolymerized SM α-actin. Although conflicting evidence exists over whether SM α-actin 
and other actin isoforms directly interact in SMCs, loss of a contractile protein may lead to 
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disruption of cytoskeletal proteins as well. Therefore it is also possible that pools of other 
unpolymerized actin isoforms in the Acta2-/- SMCs are increased, leading to proliferation 
through either of the two mechanisms described.  
 A third candidate for study is focal adhesion (FA) dependent signaling, which 
represents a group of pathways rather than a single pathway that regulate actin expression 
and polymerization as well as cell proliferation (65). Multiple factors regulate the size, 
specific composition, and the function of FAs, including the specific cell type being studied, 
the ECM composition and stiffness, the activation state of associated integrins, and the 
amount of contractile force generated by the cell (178). Integrin clustering is essential for 
FA formation and is one of the early molecular events in this process (67). The focal 
complexes formed by initial integrin clustering are short-lived structures, and contain αvβ3 
integrin, talin, paxillin, phosphorylated proteins, and FAK (179). Early FAs contain zyxin as 
well as greater quantities of the proteins recruited to focal complexes. Classical or “mature” 
FAs are 2-6 µm in length, and contain little or no tensin or α5β1 integrin (180). 
“Supermature” FAs are 8-30 µm long and contain increased amounts of vinculin and 
paxillin, in addition to tensin and α5β1 integrin (180). In contrast to FAs, fibrillar adhesions 
are mainly involved in organizing ECM and coordinating cell attachment to ECM. Fibrillar 
adhesions contain large amounts of tensin and α5β1 integrin, but vinculin, paxillin, and αvβ3 
integrin are almost entirely absent (180).  
Following FA formation, SM α-actin filament formation is a critical step in the 
process of FA development and maturation in myofibroblasts. Supermature FAs that are 
connected to SM α-actin stress fibers are required for maximal contractile force generation 
by myofibroblasts (180;181).  Inhibition of α-actin expression during myofibroblast 
99 
differentiation prevents FAs in these cells from developing into supermature FAs (182). 
When SM α-actin is expressed, but depolymerization is induced, FAs are destabilized and 
disassembled (181). Conversely, the length of the FAs formed regulates both the force 
generated by the cell and the recruitment of SM α-actin to stress fibers (180).  
 In SMCs, FA regulation is vital for maintaining SMC contractile function (178). 
FAK is an integral part of the FA complex, acting as a mechanosensor, a scaffold for 
recruitment of other proteins to these complexes, and a regulator of FA turnover (67;68). 
Knockdown of FAK expression in tracheal muscle strips resulted in decreased smooth 
muscle contractile force generation (69). SM α-actin expression in response to external 
forces is mediated in part through FAK activation (183).  FAK signaling activates multiple 
cellular pathways including Rho, Rac, PI3K, and Ras/ERK, and contributes to proliferation 
and migration in adherent cells (184;185). Increased FAK signaling also leads to increased 
proliferation and migration in multiple types of cancer (186). Expression of FRNK, an 
alternative splice variant of the FAK gene that inhibits FAK activity, prevents SMC 
proliferation (187-189). FAK is also overexpressed in diseased arteries and veins that 
display intimal hyperplasia (190). In one study, FAK promoted SMC proliferation by 
stabilizing Skp-2, an F-box protein that recognizes and degrades p27 (191). Thus, FAK is a 
key molecule at FA sites, and activates multiple major pathways to regulate cell contractility 
and proliferation.  
 Based on our data that actin filaments are disrupted in ACTA2 mutant cells, either a 
Rho/ROCK dependent or SRF dependent mechanism, or a combination of both, may drive 
increased SMC proliferation. Also, mutation or loss of SM α-actin is likely to alter FA 
structure and function, disrupting multiple signaling pathways. We hypothesize that  
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pathways with dual roles affecting both SMC contractility and proliferation are upregulated 
in Acta2-/- SMCs, driving increased proliferation. 
 
Materials and Methods 
Mouse SMC isolation and culture 
 Acta2+/+ and Acta2-/- mice were anesthetized with 400mg/kg 2.5% Avertin (2-2-2 
Tribromoethanol; Sigma-Aldrich). The ascending portion of the aorta distal to the heart and 
just proximal to the innominate artery, and the descending portion of the aorta between the 
left subclavian artery and the renal bifurcation were carefully removed. Adventitial fat was 
dissected away using a scalpel and forceps. Aortas of two mice from each genotype were 
pooled, and SMCs were explanted as previously described in Chapter II. Cells were cultured 
in SmBm supplemented with growth factors (insulin, fibroblast growth factor, and epidermal 
growth factor; Lonza), 20% FBS (Atlanta Biologicals), 1x antibiotic/antimycotic 
(Invitrogen), 2mM L-glutamine, 20mM HEPES, and 1mM sodium pyruvate.  
 Cells were plated at 70-80% confluence (100,000 cells per 35mm dish, 350,000 cells 
per 60mm dish, or 5,000 cells per 22mm round coverslip) and allowed to attach overnight in 
complete media. Prior to protein or RNA isolation, cells were placed in lower-serum 
medium without growth factors, and with 5% FBS, for 24 hours. For inhibitor assays, cells 
were treated with inhibitor at the time of serum starvation, and were incubated with inhibitor 
for 24 hours prior to harvesting cells.  
 For a subset of experiments, dishes and wells were coated with either fibronectin-1 
(20 µg/mL; Sigma) or collagen IV (0.1 mg/mL; Sigma). Dishes and wells were allowed to 
dry at room temperature overnight before cells were plated, and Collagen IV coated dishes 
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were sterilized with UV light for 20 minutes prior to performing the experiment. Plating 
SMCs on fibronectin-1 drives a more proliferative phenotype, and plating cells on collagen 
IV drives a differentiated, contractile phenotype (192). We coated plates with both of these 
matrices separately to determine whether driving either proliferation or differentiation had 
differential effects on FAK activation and localization of FA components in the wildtype vs. 
Acta2-/- SMCs.    
 
Protein isolation and immunoblotting 
 Protein isolation and immunoblotting were carried out as previously described, with 
the exception that phosphatase inhibitor cocktails I and II (10 µL/mL; Sigma-Aldrich) were 
substituted for the 10 mM NaF and 1 mM Na3VO4. Antibodies and dilutions used are listed 
in Table 1 in Chapter II.  
 
RNA isolation and quantitative gene expression analysis 
 RNA isolation and quantitative PCR were performed using Trizol, RNeasy 
purification, and Taqman gene expression assays as previously described in Chapter II. All 
data were normalized to 18S and Gapdh separately, with similar results. Data shown in 
graphs are normalized to 18S.   
 
Microarray analysis 
 Duplicate samples of total RNA isolated from explanted descending aortic SMCs 
from wildtype and Acta2-/- mice was used for study. An Agilent Bioanalyzer was used to 
confirm RNA quality. After initial amplification, RNA was labeled and hybridized to an 
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Illumina MouseWG-6 v2.0 beadchip. Illumina BeadStudio software was used to extract the 
data and confirm data quality. Genes with a differential expression score of ≥ ± 30 (p<0.001) 
were filtered for analysis. Ingenuity Pathways Analysis software was utilized to determine 
whether major canonical signaling pathways were altered in the Acta2-/- SMCs compared 
with controls (193). Genes with a twofold or greater change in expression and a p-value ≤ 
0.001 on the array were uploaded into the Ingenuity program, the altered genes were 
compared against Ingenuity’s library of canonical pathways, and statistical significance was 
automatically determined by the software using Fischer’s exact tests. Validation of selected 
genes was performed using Taqman assays on an independent set of RNA samples, as 
previously described.  
 
Cell proliferation assays 
 Cells were plated 10,000 cells/well in triplicate. Preliminary experiments were 
performed using different serum concentrations (0.2% and 5%) for different amounts of time 
in low-serum media before BrdU was added (0 hours and 24 hours), in order to determine 
optimal conditions for quantifying cell proliferation.  
 For treatment with inhibitors, cells were plated 5,000 cells/well (80-90% confluence) 
and allowed to attach overnight. 20-24 hours after plating, cells were placed in SmBm 
containing 5% FBS ± inhibitor. After 30 minutes of pre-treatment with inhibitor, cells were 
incubated with BrdU reagent for 24 hours, and a BrdU ELISA was carried out as previously 
described. The following inhibitors were used for study: U0126 (ERK), Y27632 (Rho 
kinase), PF-532,278 (FAK), and PF-562,271 (FAK/Pyk2). Experiments were performed in 
triplicate, and p-values were obtained using a Student’s t-test.  
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Histology and immunofluorescence 
 Ascending and descending aortas from wildtype and Acta2-/- mice were isolated, 
formalin-fixed and paraffin-embedded. Tissue sections were stained with H&E for analysis. 
ImageJ software (NIH) was used to measure the circumference (C) around the inner layer of 
the aortic wall, and aortic diameter was calculated by dividing C/π (77). Medial thickness 
was also measured using ImageJ. Immunofluorescence was carried out as previously 
described, with the following modifications: For phospho-FAK staining, cells were fixed in 
ice cold 50/50 methanol/acetone for 5 minutes at -20C. Following fixation, coverslips were 
rinsed 3x in PBS. For all other immunofluorescence, cells were fixed in 4% 
paraformaldehyde in 0.1M phosphate buffer, as previously described. Cells were 
permeabilized in PBS containing 0.2% saponin and 10% FBS for 10 minutes, and washed 
3x in PBS prior to blocking and staining. 5% normal donkey serum in PBS was used for 
blocking and for all antibody dilutions. Table 1 in Chapter II lists the antibodies and 
concentrations used.  
 
Transwell migration assays 
 Cells were plated 50,000 per well 0.2% FBS, in transwells containing membranes 
with 8 µm pores (BD Biosciences). The final volume in each well was 500 µL, and cells 
were plated in duplicate. Transwells were inserted into wells of a 24-well plate, containing 
5% FBS + PDGF-B (10 ng/mL), with a final volume of 750 µL per well. Plates were 
incubated for 6 hours. Transwells were washed in PBS, and cotton swabs were used to 
gently remove non-migrated cells from the upper portion of each membrane. Cells were 
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fixed in 4% paraformaldehyde for 10 minutes, washed 3x in PBS, stained with 0.5% crystal 
violet for 10 minutes, washed 3x in PBS and allowed to dry overnight. Membranes 
containing stained cells were cut from the transwell chambers and mounted onto slides using 
Permount (Fisher). Five high-powered fields from each transwell membrane were 
photographed by a blinded observer, and the cells per high-power field were counted.  
 
Rho activation assay 
 A Rho pulldown assay was performed to determine whether more active RhoA was 
present in the Acta2-/- SMCs. SMCs were seeded at 80-90% confluence in a T75 culture 
flask and allowed to adhere overnight. Cells were serum-starved for 24 hours, and were 
stimulated with complete media containing 20% FBS one hour prior to the assay. Assay 
components were purchased from Cell Biolabs, Inc. (San Diego, CA). All work was 
performed in a coldroom. Cells were washed 2x in PBS, and flasks were incubated on ice 
1mL lysis buffer for 10 minutes and then scraped. Cell lysates were passed through a 27½ 
gauge needle to shear genomic DNA, and 60 µL of total lysate was set aside for protein 
quantification and for immunoblotting of total RhoA. Lysates were centrifuges at 13,000 x g 
for 10 minutes. Agarose beads conjugated to a Rho binding domain were resuspended, 40 
µL of beads was added to each tube, and samples were incubated for 1 hour at 4ºC with 
gentle shaking. Samples were centrifuged at 13,000 x g for 10 seconds, supernatant was 
carefully removed and discarded, and samples were washed in 500 µL lysis buffer. The 
wash was repeated a total of 3 times. After the final wash, the bead pellet was resuspended 
in 2x reducing sample buffer, boiled for 5 minutes, and centrifuged at 13,000 x g for 10 
seconds. Equal volumes of the pull-down assay supernatant, along with the total protein 
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samples, were separated on a 10% polyacrylamide gel, transferred to a PVDF membrane, 
and immunoblotted for RhoA.  
 
Results 
Characterization of the aortic phenotype in Acta2-/- mice 
 ACTA2 mutations cause aneurysms in humans; however, an aneurysm phenotype had 
not been previously described in Acta2-/- mice. Therefore we wanted to determine whether 
loss of SM α-actin in Acta2-/- mice also led to aneurysm formation. Ascending aortas from 
Acta2-/- mice were significantly larger than wildtype at 10-12 weeks of age, indicating the 
beginnings of aneurysm formation. Gross examination of the aortic tissue showed 
enlargement of the ascending aortas in Acta2-/- mice compared with wildtype. No obvious 
enlargement of the descending aorta was present (Figure V-1A).  
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Figure V-1. Aortic aneurysms in Acta2-/- mice. Acta2-/- mice display ascending aortic 
enlargement accompanied by increased proteoglycans and increased thickening and 
cellularity in the vessel wall. (A) Upon gross examination, formalin-fixed ascending aortas 
of 10-12 week old Acta2-/- mice appeared larger than age matched wildtype. There were no 
apparent differences in the descending aorta. Scale bars represent 1.0mm. (B) H&E staining 
(top two panels) revealed enlargement of the ascending aorta in Acta2-/- mice, along with 
asymmetric thickening of the vessel wall and increased SMCs in the aortic media. Movat 
staining (bottom panel) showed some proteoglycan accumulation (blue) in the Acta2-/- 
aorta. Top panel is magnified 40x and middle and bottom panels are magnified 200x. Scale 
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bars represent 500 µM. (C) Aortic diameter was measured using ImageJ analysis software, 
and is significantly larger in 8-12 week old Acta2-/- mice (n=6) than age matched wildtype 
(n=6). (D) Counting of medial SMCs showed increased SMCs in Acta2-/- aortas (n=6) 
compared with wildtype (n=6). Cells in five high powered fields were counted for each 
aortic tissue sample. Data for (C) and (D) are shown ± S.D. *p<0.05.  
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Histologic examination of ascending aortic tissue confirmed this enlargement (Figure 1B). 
We used ImageJ software to measure the inner circumference of the aortic wall and then 
calculated aortic diameter (Figure 1C). The diameter was significantly enlarged in 8-12 
week old Acta2-/- mice (n=6) compared with age matched controls (n=6), and this change 
was visibly apparent in the tissue in mice as young as 8 weeks.  
Aortic aneurysms are associated with medial degeneration of the aorta, characterized 
by proteoglycan accumulation and elastic fiber loss and fragmentation. We used Movat 
staining to visualize ECM components in the aorta to determine whether medial 
degeneration was present in the dilated aortas from Acta2-/- mice. Proteoglycan expression 
was slightly increased in Acta2-/- compared with wildtype aorta (Figure V-1B). The aortic 
wall also appeared asymmetrically thickened in Acta2-/- mice. To determine whether this 
thickening was associated with increased numbers of SMCs in the medial layer, we counted 
cells under high powered fields (400x; n=4 mice per genotype) and found that Acta2-/- aortas 
had increased SMCs (Figure V-1D).  
Overall, these data show a previously undescribed aneurysm phenotype in Acta2-/- 
mice, accompanied by an increase in the number of SMCs present in the vascular wall, and 
minimal changes typical of medial degeneration. Based on these data and on previously 
108 
published data, Acta2-/- mice are likely to be a suitable model for our studies of SMC 
proliferation in association with aneurysm formation.  
 
Increased proliferation and migration in Acta2-/- SMCs 
 Previous studies reported increased proliferation in Acta2-/- renal myofibroblasts 
(124). Based on these data and on our data showing increased proliferation in ACTA2 mutant 
SMCs and myofibroblasts, we hypothesized that the Acta2-/- SMCs would also demonstrate 
increased proliferation and would provide a suitable model system. Our initial experiments 
to test culture conditions showed that serum deprivation using 5% FBS at the time of BrdU 
incubation yielded the best and most consistent results. Therefore, this experimental setup 
was used for the remainder of the cell proliferation assays. Similar to ACTA2 mutant SMCs 
and myofibroblasts, Acta2-/- SMCs explanted from both the ascending and descending aorta 
proliferate significantly more rapidly than wildtype in vitro (Figure V-2A).  
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Figure V-2. Increased proliferation and migration in Acta2-/- SMCs. (A) SMCs explanted 
from both the ascending and descending aortas of Acta2-/- mice proliferated significantly 
more rapidly than wildtype. (B) Transwell migration assays showed that Acta2-/- SMCs in 
0.2% FBS migrated more rapidly toward a gradient of 5% FBS + 10ng/mL PDGF than 
wildtype. The experiment was performed in duplicate wells and repeated three times. 
Results were quantified by counting the number of migrated cells per high powered 
microscope field on the transwell membrane. Five separate fields were counted per sample, 
and representative images of cells on the transwell membrane are shown. Interestingly, 
Acta2-/- SMCs display slightly elongated morphology compared with wildtype. Error bars 
represent ± S.E.M. *p<0.05 
************************************************************************** 
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Since increased migration was also described in Acta2-/- myofibroblasts, we performed 
transwell migration assays to determine whether Acta2-/- SMCs also displayed increased 
migration (124). We used a transwell assay rather than a scratch or wounding assay because 
it allowed for assessment of cell migration in response to a chemotactic gradient (10 ng/mL 
PDGF-B). However, one disadvantage was that we were unable to monitor changes in cell 
shape during migration. Descending Acta2-/- SMCs migrated more rapidly than wildtype 
toward the PDGF-B gradient (Figure V-2B). These data indicate that Acta2-/- SMCs are a 
suitable model for studying SMC proliferation in response to a contractile protein defect, 
and suggest that increased SMC migration may be important as well.  
 
ROCK and ERK inhibitors partially but not completely block proliferation 
 Based on the role that Rho/ROCK plays in actin polymerization and also in SMC 
proliferation, we hypothesized that Rho was overactivated in Acta2-/- mice, in response to 
the inherent contractile defect. Treatment of Acta2-/- SMCs with a ROCK inhibitor, Y27632, 
resulted in decreased proliferation in both Acta2-/- and wildtype SMCs, although only the 
decrease in Acta2-/- SMC proliferation was significant (Figure V-3A).  
 
111 
Figure V-3. Rho and ERK inhibitors partially block Acta2-/- SMC proliferation. (A) 
Treatment of SMCs with either a Rho kinase inhibitor (Y27632) or an ERK inhibitor 
(U0126) caused a significant decrease in proliferation in Acta2-/- SMCs but failed to 
completely block the proliferation compared to wildtype. For the ERK inhibitor, DMSO was 
added to the untreated cells to control for the DMSO present in the inhibitor solution. Data 
shown are a mean of three observations and error bars represent ± S.D. *p<0.05. (B) A Rho 
pulldown assay failed to show a difference in GTP-bound RhoA in Acta2-/- mice compared 
to wildtype. Additionally, p27 expression remained the same. Since p27 is degraded in 
response to RhoA activation, these data suggest that a Rho/p27 mediated mechanism is not 
likely driving proliferation.  
************************************************************************** 
Since doses of 10, 20, and 30 µM were used to block Rho activation and proliferation in 
TSC2-/- cells, we treated Acta2-/- SMCs with the same doses (194). However, even the 
highest dosage of 30 µM failed to completely prevent increased proliferation. Since the 
ROCK inhibitor partially inhibited proliferation, we used a Rho pulldown assay to determine 
whether RhoA activation was increased. We did not observe any difference in Rho activity 
between the Acta2-/- and wildtype SMCs (Figure V-3B). Since small changes in RhoA can 
be difficult to detect using this assay, we immunoblotted for p27, since it is known to be 
degraded in response to Rho activation (169). However, p27 levels were not altered. 
Together, these data suggest that Rho/ROCK activation plays a role in overall SMC 
proliferation, but is not the main pathway driving proliferation in the Acta2-/- SMCs.  
 We also hypothesized that a switch between SRF/MRTF and SRF/TCF mediated 
gene expression, in concert with growth factor stimulated ERK activation, might be driving 
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proliferation. We labeled SMCs with MRTF-A to determine subcellular localization. We 
expected to find increased cytoplasmic localization; however, immunofluorescent labeling 
failed to yield interpretable results. QPCR analysis of c-fos, a gene known to be induced by 
SRF/TCF, showed that steady state expression levels were not increased in the Acta2-/- 
SMCs (not shown). We hypothesized that an increase in G-actin leads to increased 
cytoplasmic localization of MRTFs. We also hypothesized that in the complete absence of 
SM α-actin, β-actin filaments would be disrupted. However, immunofluorescent labeling of 
β-actin did not reveal an appreciable difference in β-actin filaments between the wildtype 
and Acta2-/- SMCs. Overall, we were unable to conclusively determine whether SRF 
mediated signaling contributes to the proliferation. Since IGF-1 was increased in ACTA2 
mutant SMCs and myofibroblasts, and is also known to activate ERK signaling, we 
hypothesized that IGF-1 along with ERK activation would be increased and potentially drive 
proliferation. However, in contrast to ACTA2 mutant SMCs and myofibroblasts, we did not 
find any change in IGF-1 gene expression in Acta2-/- SMCs, suggesting that either other 
growth factors or other cellular pathways may be more important in the proliferative 
phenotype. Similar to the ROCK inhibitor, an ERK inhibitor, U0126, partially blocked but 
did not fully prevent increased proliferation in the Acta2-/- SMCs (Figure V-3A). 
Additionally, untreated Acta2-/- SMCs failed to show consistent increases or decreases in 
phosphorylated ERK (not shown). Taken together, these data suggest that although ERK 
activation may drive part of the increased proliferation, additional cellular pathways are 
involved.  
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Gene expression analysis in Acta2-/- SMCs 
 We used Ingenuity Pathway Analysis software to determine whether canonical 
pathways were altered in the Acta2-/- SMCs, leading to proliferation. Interestingly, the top 
canonical pathway identified by Ingenuity was Hepatic Fibrosis/Hepatic Stellate Cell 
Activation (p = 5.72E-10). Hepatic stellate cells are capable of transitioning to a 
myofibroblast-like proliferative phenotype and producing excessive ECM proteins 
(particularly collagen) in response to injury, and both the proliferation and ECM production 
are dependent on FAK signaling (195). Since both FAK and procollagen 1 expression were 
increased in Acta2-/- renal myofibroblasts, we would expect to find increased collagen 
production as well as FAK in the Acta2-/- SMCs (124). Since FAK is an integral part of FAs, 
we also looked for alterations in any genes known to be associated with focal adhesions 
(196). We found alterations in genes associated with ECM production and FAs, as well as 
genes associated with the SMC contractile complex and cell adhesion. A summary of these 
genes is listed in Table 4.  
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Table 4. FA, ECM, adhesion, and contractile genes altered in Acta2-/- SMCs. 
Contractile apparatus Focal adhesion-related genes 
Gene  Protein name Fold change Gene  Protein name Fold change 
Actg2* actin, gamma 2, smooth muscle, 
enteric 24.78 Itga5 
integrin alpha 5 (fibronectin 
receptor alpha) 2.24 
Myh11* myosin, heavy polypeptide 11, 
smooth muscle 8.44 Itga11 integrin, alpha 11 3.98 
Smtn smoothelin 2.26 Itgb4 integrin beta 4, transcript variant 2 4.83 
Tagln transgelin 3.81 Lims2 LIM and senescent cell antigen like domains 2 (pinch2) 3.58 
Tpm2 tropomyosin 2, beta 2.12 Fhl2 four-and-a-half LIM domains 2 3.25 
Tpm1 tropomyosin 1, alpha 1.58 Palld palladin 3.43 
Acta2* actin, alpha 2, smooth muscle -8.96 Bmx BMX non-receptor tyrosine kinase (Etk) 3.06 
Extracellular Matrix Csrp1 cysteine and glycine-rich protein 1 3.01 
Gene  Protein name Fold change Flnb filamin B 2.15 
Eln elastin 8.09 Cav1 caveolin, caveolae protein 1 1.96 
Col12a1 procollagen, type XII, alpha 1 7.99 Vim vimentin 1.77 
Col18a1 procollagen, type VIII, alpha 1 7.03 Rac3 RAS-related C3 botulinum 
substrate 3 1.65 
Col6a3 procollagen, type VI, alpha 3 6.76 Nck2 non-catalytic region of tyrosine kinase adaptor protein 2 1.61 
Col3a1 procollagen, type III, alpha 1 4.36 Sorbs1 ponsin 1.58 
Col15a1 procollagen, type XV 3.88 Actn1 actinin, alpha 1 1.57 
Col7a1 procollagen, type VII, alpha 1 3.57 Tgfb1i1 TGF-β1 induced transcript 1 1.49 
Col6a2 procollagen, type VI, alpha 2 2.95 Sdcbp2 syntenin 2 1.44 
Col5a1 procollagen, type V, alpha 1 2.79 Rapgef1 Rap GEF 1 1.42 
Col10a1 procollagen, type X, alpha 1 2.75 Ptk2b protein tyrosine kinase 2 beta  1.37 
Col4a1 procollagen, type IV, alpha 1 2.51 Itgb1bp1 integrin beta1 binding protein 1  1.36 
Col4a2 procollagen, type IV, alpha 2 2.38 Vcl vinculin 1.22 
Fn1 fibronectin 1 2.08 Parva parvin, alpha -1.25 
Col6a1 procollagen, type VI, alpha 1 2.01 Zyx zyxin -1.30 
Col1a2 procollagen, type I, alpha 2 1.94 Ppfia1 liprin -1.46 
Col5a2 procollagen, type V, alpha 2 1.52 Sdcbp syntenin 1 -1.54 
Col16a1 procollagen, type XVI, alpha 1 1.33 Vil2 ezrin -1.57 
Col4a5 procollagen, type IV, alpha 5 -1.36 Pfn2 profilin 2 -1.58 
Col8a1 procollagen, type VIII, alpha 1 -1.75 Tln2 talin 2 -1.64 
Col4a6 procollagen, type IV, alpha 6 -5.62 Prkcm polycystin-1 -1.69 
Col28a1 collagen, type XXVIII, alpha 1 -6.26 Pfn2 profilin 2 -1.78 
Cadherins Pak4 p21 protein-activated kinase 4 -2.42 
Gene  Protein name Fold change Other 
Cdh5 cadherin 5 (VE-cadherin) 6.15 Gene Protein name Fold change 
Cdh13 cadherin 13 (T-cadherin) 4.83 Pip5k1b* PIP5 kinase, type 1 beta 13.49 
Pcdh9 protocadherin 9 -3.79 Srpx2 Sushi repeat protein X-linked 2  11.40 
Pcdh21 protocadherin 21 -3.80       
Gm1010 cadherin-like 26 -3.99 *denotes validation by Q-PCR   
Cdh3 cadherin 3 (P-cadherin) -4.77 
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Table 4. FA, ECM, adhesion, and contractile genes are altered in Acta2-/- SMCs. 
Acta2-/- SMCs displayed increased ECM production, including elastin, fibronectin 1, and 
fifteen different collagen genes. Multiple FA-associated and adhesion genes are also altered, 
suggesting that these SMCs are fibrogenic and have altered adhesive properties. The fold 
change listed is the relative expression level in Acta2-/- SMCs compared with wildtype. An 
asterisk denotes validation via QPCR.  
************************************************************************** 
 FAK gene expression was unaltered, and this was confirmed via QPCR; however, 
fifteen different collagen genes were upregulated, and twelve of these were increased by 
twofold or more. Only four collagen genes were downregulated, and two were decreased by 
more than twofold. Elastin and fibronectin also were upregulated eightfold and twofold, 
respectively. Since ECM overproduction is a characteristic feature of de-differentiated 
SMCs and ECM accumulation is evident in the intimal lesions in humans, we hypothesized 
that Acta2-/- SMCs exhibit a de-differentiated phenotype. However, expression of multiple 
terminal SMC differentiation markers were either unaltered or were increased in the Acta2-/- 
SMCs. Out of these genes, we validated increased expression of Myh11 and Actg2. Calponin 
1 is an additional marker of differentiated SMCs: although this gene was not listed in the 
array results, QPCR analysis showed that this gene was also increased in Acta2-/- SMCs. All 
of these gene expression data suggest a differentiated, contractile SMC phenotype rather 
than a de-differentiated phenotype. Additional evidence that these SMCs are not de-
differentiated is S100A4 expression. S100A4 is a marker for de-differentiated SMCs in 
culture, but was not increased in Acta2-/- SMCs (197). The most highly upregulated gene on 
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the array was Actg2, encoding SM γ-actin, and was increased 24.78-fold. These data are 
consistent with SM γ-actin increases reported by Takeji et al (124). 
 A number of genes encoding proteins that are known to be associated with FAs were 
altered in the Acta2-/- SMCs. Out of these alterations, twenty-two genes were upregulated, 
and nine of these genes were increased by twofold or greater. Ten genes were 
downregulated, and only one gene was downregulated by more than twofold. Of note, 
several integrin receptor levels are increased in the Acta2-/- SMCs: β4, α5, and α11. Several 
kinases, either associated directly or potentially associated with FAs, were also increased, 
including Etk, FAK2, and Pip5k1b. Although not directly localized to FAs under normal 
conditions, Pip5k1b has the potential to localize to the cell membrane when overexpressed 
(198). Also, Pip2 production within the cell has the potential to influence and regulate FA 
dynamics (198). Therefore, although not included in the final count of upregulated FA-
related genes, Pip5k1b may be relevant for the study of FA alteration in the Acta2-/- SMCs.  
 Other adhesion-related genes were also altered in Acta2-/- SMCs. Cadherin 13 was 
upregulated 4.83-fold and is of particular interest because this protein, unlike other 
cadherins, has anti-adhesive properties, and its expression is associated with increased cell 
migration and proliferation, as well as alterations in FA localization with the cell (199). 
SMCs from Acta2-/- mice are generally more elongated in culture, and this change is 
particularly evident in the descending SMCs (Figure V-2B). The elongated phenotype, 
coupled with overexpression of cadherin-13, is consistent with reports of cells that have 
been transfected with cadherin-13 or that have been plated on a cadherin-13-containing 
substrate(199). Srpx2 (Sushi repeat containing protein, X-linked 2) gene expression was also 
highly upregulated (11.4-fold). Recently, this protein was found to increase FAK activation 
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in gastric cancer (200). Collectively, these microarray data suggest that FAs are altered in 
Acta2-/- SMCs.  
 
Focal adhesions are altered in Acta2-/- SMCs 
 Vinculin is a marker for mature FAs, and tensin is a general marker for fibrillar 
adhesions. Since tensin and vinculin colocalization is an indicator of supermature FAs in 
differentiated myofibroblasts, we double-immunolabeled Acta2-/- and wildtype SMCs with 
these markers to determine if FA maturation was altered in the Acta2-/- SMCs (180). Tensin 
immunofluorescence showed a small amount of tensin-vinculin colocalization in the 
wildtype compared to Acta2-/- SMCs, possibly due to vinculin localization more at the cell 
periphery in the Acta2-/- SMCs than in wildtype (Figure V-4A).  
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Figure V-4. Altered localization of FA components in Acta2-/- SMCs. 
(A) Since tensin and vinculin colocalize in supermature FAs, we double labeled Acta2-/- and 
wildtype SMCs with tensin and vinculin. A small amount of tensin and vinculin 
colocalization is present in the wildtype but not Acta2-/- SMCs, possibly due to vinculin 
localization more at the cell periphery in Acta2-/- SMCs. (B) Vinculin-containing FAs 
(green) are localized more to the cell periphery in Acta2-/- SMCs than in wildtype SMCs. 
Results are representative of cells plated on collagen IV coated, fibronectin-1 coated, or 
uncoated coverslips, from two separate experiments. This staining pattern can also be seen 
in panel A. Staining of actin stress fibers (red) confirmed vinculin localization at adhesion 
sites at the ends of the actin fibers. Since vinculin is a definitive marker for FAs, these data 
confirm that FAs are altered in Acta2-/- SMCs compared to wildtype. (C) Since zyxin 
localizes to FAs but translocates to actin stress fibers or to the nucleus when cells are 
exposed to mechanical force, we immunofluorescently labeled SMCs with zyxin (green) and 
observed consistent alterations in zyxin staining patterns. In wildtype SMCs zyxin was 
localized to some adhesion sites at the cell periphery, and also localized in a punctate pattern 
within the perinuclear region of the cell. In Acta2-/- SMCs, zyxin exhibited a distinct, tubular 
staining pattern that was neither perinuclear nor localized to actin stress fibers. The 
subcellular structure(s) that zyxin is localizing to in these cells has not yet been determined; 
however, together these data support that FAs are altered in Acta2-/- SMCs. Cells shown 
were plated on fibronectin-1; similar and consistent results were obtained for cells plated on 
collagen IV and on uncoated coverslips.  
**************************************************************************
 Since vinculin is a widely used marker for FAs, we double immunolabeled cells with 
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vinculin along with phalloidin, so that both FAs and actin filaments within the cell could be 
visualized. We observed that vinculin is consistently localized more to the cell periphery in 
the Acta2-/- SMCs than in wildtype (Figure V-4A,B). Similar localization patterns have been 
observed in fibroblasts that lack integrin-linked kinase (another FA-associated protein) and 
in SMCs that overexpress cadherin 13 (199;201).  
  Zyxin localizes to mature FAs, but also acts as a sensor and transducer of mechanical 
force in SMCs and moves from the FAs to the actin filaments with the application of 
mechanical force to cells (202;203). Since Acta2-/- mice have decreased aortic contractility, 
we hypothesized that localization of a mechanosensitive FA marker would be altered in 
these cells compared with wildtype. Whereas in wildtype mice zyxin was present in FAs at 
the cell periphery and in more punctate patterns in the perinuclear region, in Acta2-/- SMCs 
zyxin was formed into long, tortuous rodlike structures that do not localize with the β-actin 
filaments or in the nucleus (Figure V-4C). Based on these studies, zyxin localization is 
altered in the Acta2-/- SMCs but the etiology of the rod shaped structures that appear with 
zyxin staining in the null cells has not been determined.  
 Fibronectin-coated coverslips were used for all of the immunofluorescence studies 
for several reasons: 1) fibronectin drives FA formation in SMCs and therefore should 
highlight any problems with FA formation in the Acta2-/- SMCs, and 2) the most consistent 
inhibition of cell proliferation with two different FAK inhibitors (described below) was 
obtained using cells plated on fibronectin. While all results shown are from SMCs plated on 
fibronectin coated coverslips, SMCs plated on both collagen IV and uncoated coverslips 
produced similar results.  
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 Since FAK is important for scaffolding as well as regulating FA formation and 
turnover, we immunostained and immunoblotted for phosphorylated FAK. Immunoblotting 
showed a slight increase in FAK in the descending but not the ascending SMCs, and 
immunoblot results from the descending SMCs are shown in Figure V-5A.  
 
Figure V-5. FAK dependent proliferation in Acta2-/- SMCs. (A) Immunoblotting showed 
that pY397 FAK and total FAK are increased in descending Acta2-/- SMCs when plated on 
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uncoated or collagen IV coated matrices. The difference was less apparent in cells plated on 
fibronectin-1. (B) pY397 FAK is localized more to FAs at the cell periphery in Acta2-/- 
SMCs. This was consistent for both ascending (top two panels) and descending (bottom two 
panels) SMCs. Additionally, pY397 FAK staining at FAs appears more intense in Acta2-/- 
SMCs than in wildtype. (C-E) The FAK inhibitor PF-562,271 completely blocked increased 
proliferation in Acta2-/- SMCs plated on uncoated plates (C), and fibronectin-1 or collagen 
IV coated plates (D and E, respectively). A second FAK inhibitor, PF-532,278, completely 
blocked proliferation on fibronectin-1 coated surfaces but not uncoated or collagen IV 
coated surfaces (not shown). Together, these data indicate that Acta2-/- proliferation is 
dependent on FAK signaling. Experiments were performed in triplicate, and data are shown 
± S.D. *p<0.05, **p<0.01, ns = not significant.  
************************************************************************** 
Densitometry did not yield a statistically significant difference in increased FAK between 
the Acta2-/- and wildtype SMCs. However, immunofluorescent staining revealed alterations 
in the localization of phosphorylated FAK in Acta2-/- compared with wildtype SMCs. 
Phosphorylated FAK is concentrated at focal adhesions at the cell periphery (Figure V-5B). 
Although FAK can be autophosphorylated within the cytoplasm, FAK that is actively 
signaling is only found in FAs (204). Therefore, the stronger localization of phosphorylated 
FAK at the cell periphery in FAs in Acta2-/- SMCs suggests that FAK signaling is increased, 
even though total levels of FAK are not dramatically altered.  
 
Multiple FAK inhibitors block increased proliferation in Acta2-/- SMCs 
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 SMCs plated on collagen, fibronectin, or uncoated 96-well plates were treated  ± 
either of two FAK inhibitors, PF-532,278 or PF-562,271. We initially chose to use PF-
532,278 because of its availability and specificity (205). This inhibitor completely blocked 
proliferation of the Acta2-/- SMCs plated on fibronectin-1 but only partially blocked 
proliferation in cells plated on collagen IV or uncoated plates (data not shown). To confirm 
the results, we obtained PF-562,271, a molecule that is currently in clinical trials for 
treatment of cancer (206). In contrast to the first FAK inhibitor, PF-562,271 completely 
prevented increased proliferation in Acta2-/- SMCs plated on all of the three matrices. 
Results are shown for fibronectin-plated cells treated ± PF-562,271 (Figure V-5C). Similar 
results were obtained for cells plated on uncoated or fibronectin-1 coated matrices ± PF-
562,271, and also for cells plated on fibronectin-1 coated matrices ± PF-532,278 (not 
shown). Together, these data suggest that FAK dependent signaling is at least in part driving 
the observed proliferation in Acta2-/- SMCs.  
 
Discussion 
 Acta2-/- mice are the first mouse model of aortic disease caused by disruption of a 
SMC-specific contractile protein. Additional characterization of these mice and in vivo 
quantification of the increases in aortic diameter should confirm this finding. Aortas in mice 
as young as 8 weeks are enlarged compared with wildtype, and aortas were previously 
shown to display decreased contractility, suggesting that these mice are a good model for 
studying aneurysm formation due to an inherent SMC contractile defect. Since other existing 
mouse models of aortic aneurysms focus on the contribution of TGF-β1 signaling and/or 
extracellular matrix proteins, a mouse model with an SMC contractile defect represents a 
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unique opportunity to define novel pathways leading to aneurysm formation. Establishment 
of this model is important for our understanding of thoracic aortic disease. The FBN1 mouse 
recapitulates the aneurysms found in MFS, which involve initially the sinuses of Valsalva. 
In contrast, aneurysms in patients with ACTA2 mutations are the more common form of 
aneurysm, sparing the sinuses of Valsalva and involving the ascending aorta. These are also 
the type of aneurysms that form due to chronic hypertension. The Acta2-/- mice showed 
enlargement of the ascending aorta and should be particularly useful in determining the 
differences in pathogenesis between aneurysms due to MFS and aneurysms caused by either 
hypertension or ACTA2 mutations.   
 Increased SMC numbers in aortic tissue indicate that Acta2-/- mice are a good model 
for studying the contribution of cell proliferation to aortic aneurysm formation as well. We 
observed increased SMCs and expansion of the vessel wall were found prior to significant 
medial degeneration in Acta2-/- mice. This is in contrast to aneurysm formation in MFS 
mouse models, where medial degeneration occurs at an early stage and increased SMCs in 
the medial layer are not observed (10). The observation that one of the initial pathologic 
features in the Acta2-/- aortas is SMC proliferation suggests a potential role for proliferation 
in aneurysm formation in this mouse, and raises the question of whether SMC proliferation 
drives aneurysm formation in ACTA2 mutant aortas. Recent pathologic examination of 
aortic tissues from patients with an exceptionally severe ACTA2 mutation, R179C, support 
this idea (Dianna Milewicz, personal communication). Aneurysmal tissue from these 
patients showed minimal medial degeneration coupled with subintimal SMC hyperplasia.  
Through study of Acta2-/- SMCs, we have made several important observations: 
alterations in expression of FA-associated genes, peripheral localization of FAs, increased 
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pFAK localization in FAs, and increased proliferation that is dependent at least in part on 
FAK.  Altered vinculin localization in Acta2-/- SMCs provides evidence of disruption of both 
FAs and contractile force generation by the cell. Vinculin incorporation into FAs is required 
for generation of force by SMCs and is thought to be proportional of the amount of force 
being generated by the cell (207). This idea is consistent with the decrease in vinculin-
containing adhesions across the cell body of Acta2-/- SMCs, and also agrees with previously 
published data that Acta2-/- aortas (and by implication also, Acta2-/- SMCs) have decreased 
ability to contract in vivo (117). Further, the stability of focal complexes at the cell 
periphery may be altered, and future work will determine whether FA turnover is increased 
in Acta2-/- compared to wildtype SMCs. The increased migration observed in the Acta2-/- 
SMCs is consistent with a rapid rate of FA assembly and disassembly (179).  
 Changes in localization of zyxin suggest that Acta2-/- SMCs have an altered ability to 
transduce force signals. Zyxin is a mechanosensitive component of FAs that is translocated 
to either actin stress fibers or to the nucleus when the cell is placed under mechanical stress, 
and may also act to reinforce the cell cytoskeleton (202;203). Future work will identify the 
subcellular structure that zyxin is localizing to within Acta2-/- SMCs.   
 In addition to the observed alterations in other FA proteins, FAK expression and 
localization is also altered. In the descending SMCs, FAK expression is increased, consistent 
with data from Acta2-/- myofibroblasts (124). However, unlike the myofibroblasts, this 
increase was not nearly as pronounced, and was not statistically significant. This could be 
due to inherent differences between myofibroblasts and SMCs.  
 Similar to patterns of vinculin immunofluorescent staining, phosphorylated FAK is 
localized more at FAs at the cell periphery in Acta2-/- SMCs compared to wildtype. Since 
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these cells also migrate more rapidly in culture, these data are consistent with other reports 
of FAK localization to peripheral FAs during cell migration (204). FAK is found primarily 
at FAs but can be localized in the cytoplasm or nucleus as well. Phosphorylated FAK 
(Y397) is found mainly at FA sites along the cell periphery, but can also be 
autophosphorylated while still in the cytoplasm and/or localized to FAs further away from 
the edge of the cell (204). Transfecting cells with a C-terminal fragment of FAK displaced 
FAK from FAs and reduced proliferation and migration, showing that localization of FAK 
to FAs is required for fully functional signaling (185). Thus, despite the fact that 
immunoblotting did not reveal large differences in FAK phosphorylation, the 
immunofluorescence data show more FAK localization at the cell periphery, suggesting that 
FAK is altered in Acta2-/- SMCs.  
 Multiple FAK inhibitors were successful in blocking proliferation in Acta2-/- but not 
wildtype SMCs plated on fibronectin-1, suggesting that Acta2-/- proliferation is at least in 
part dependent on FAK. However, both of the kinase inhibitors used target FAK as well as 
several other nonspecific targets (205;206). PF-562,271 also inhibits Pyk2 (FAK2), which 
also localizes to the cell membrane and can drive proliferation when activated (208). 
Although Pyk2 is not nearly as highly expressed as FAK in SMCs, Pyk2 mRNA expression 
is marginally increased (1.37-fold) in Acta2-/- SMCs. This increase in expression has not yet 
been validated, and the role of Pyk2 in Acta2-/- SMC proliferation remains unknown. PF-
562,271 appears to be a more potent inhibitor of Pyk2 than PF-573,228, which may explain 
why only partial inhibition of proliferation was achieved on uncoated and collagen-coated 
matrices using this inhibitor. Thus, while localization of phosphorylated FAK is clearly 
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altered in the null SMCs, we cannot rule out the possibility that the complete inhibition of 
proliferation is due to the dual inhibition of FAK and Pyk2 (205;206). 
 Microarray analysis revealed increased SMC contractile gene expression, increased 
collagen gene expression, and alterations in a number of FA-associated genes. Since Acta2-/- 
SMCs were more proliferative and showed increased levels of ECM genes, we expected 
these cells to have a more de-differentiated phenotype. However, contrary to our 
expectations, Acta2-/- SMCs had increased expression of multiple markers of mature SMCs, 
including Myh11 and Cnn1. Additionally, these SMCs did not display increased expression 
of S100A4, a marker of dedifferentiated, proliferative SMCs. These data indicate that  
Acta2-/- SMCs are proliferating in the absence of phenotypic switching, and agree with other 
observations that contractile and synthetic SMCs do not necessarily represent two mutually 
exclusive SMC phenotypes (56). 
 Multiple genes on the microarray suggest that FAs and potentially cell adhesion are 
altered, and future study will determine whether these alterations play a role in regulating 
proliferation. Cadherin-13 is of particular interest because of its anti-adhesive properties and 
the fact that its expression correlates with SMC proliferation (209). Another potential gene 
for follow-up is caveolin-1, which was upregulated 1.96-fold in Acta2-/- SMCs. 
Phosphorylated caveolin-1 is necessary but not sufficient to stabilize FAK within FAs and 
promote FA turnover (210). A third gene that deserves further study is Pip5k1b. The 
observation of increased Pip5k1b expression in the Acta2-/- SMCs raises the question of 
whether Pip2 production is altered at FAs in these cells. Although the α and β isoforms of 
Pip5k1 are not directly associated with FAs, the γ isoform is, and all of the Pip5k1 isoforms 
are responsible for some of the Pip2 production within the cell. Pip2 promotes the nucleation 
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of new actin filaments by causing the release of gelsolin from actin (211). Pip2 also plays a 
role in FAK activation; however, localization within the cell is important. It remains to be 
determined whether Pip5k1b protein levels are increased, and whether increased Pip2 
production within the cytoplasm plays a role in FA signaling in the Acta2-/- SMCs. A fourth 
adhesion-related gene, Srpx2 (Sushi repeat containing protein, X-linked 2), may be 
interesting for follow-up as well. As previously mentioned, this protein is capable of 
activating FAK and promoting cell adhesion and migration in gastric cancer (200). All of 
these genes have potential relevance to both FAK and cell proliferation, and support a role 
for FAK regulation of proliferation in Acta2-/- SMCs. Future work will elucidate the role of 
these genes in Acta2-/- SMC proliferation. 
 In these studies, we have described for the first time alterations in both FA gene 
expression and protein localization in Acta2-/- SMCs, along with a role for FAK in driving 
increased proliferation in these cells. Since SM α-actin stabilizes FAs to allow for generation 
of contractile force, an inability to form SM α-actin filaments could result in increased FAK-
mediated turnover of FAs and/or inability of the cells to form fully mature FAs capable of 
transducing mechanical force and responding to mechanical stress. Our data showing altered 
vinculin, zyxin, and phospho-FAK localization supports the idea that the Acta2-/- SMCs are 
unable to generate sufficient tension. The fact that FAK inhibitors reduced proliferation in 
Acta2-/- SMCs to levels equal to wildtype SMCs suggests a role for FAK signaling in driving 
Acta2-/- SMC proliferation. Thus, the altered FAK localization and signaling may be a 
compensatory mechanism resulting from the inability of Acta2-/- SMCs to generate sufficient 
intracellular tension.    
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 Our data suggest Acta2-/- SMCs have decreased ability to respond to mechanical 
stress; therefore, stretching the SMCs in vitro may reveal even more pronounced alterations 
in FAs.  Future studies will determine whether this is the case, by exposing the cells to 
cyclic mechanical strain on a Flexcell apparatus. Additionally, the specific downstream 
pathways activated by FAK to induce proliferation in Acta2-/- SMCs remain undefined, and 
future work will determine whether a specific downstream pathway or a combination of 
pathways are driving proliferation. Based on our current data, we predict that multiple 
pathways are likely to contribute.  
 In addition to these in vitro studies, we also plan to determine SMC proliferation in 
vivo in the Acta2-/- mice is dependent on FAK, using an established carotid injury model. 
Data generated using this model show that Acta2-/- mice have a greater proliferative response 
to vascular injury than wildtype mice, and we expect that a FAK inhibitor will prevent this 
proliferation in vivo. Finally, it will be exciting to determine whether FA alterations and 
FAK signaling are altered in patients heterozygous for ACTA2 or MYH11 mutations. 
Disruption of an SMC-specific contractile protein leading to an increase in FAK-dependent 
proliferation may represent a novel pathway leading to the combined phenotype of familial 
TAAD and vascular occlusive disease.  
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CHAPTER VI 
DISCUSSION 
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 We have identified a novel vascular pathology caused by mutations in the SMC-
specific contractile genes MYH11 and ACTA2. These studies provide the pathologic and cell 
biology data to support the hypothesis that a single gene defect can cause diverse vascular 
diseases in multiple arteries throughout the body. Furthermore, our data suggest two 
differing effects of ACTA2 mutations on SMCs: a loss of function, leading to decreased 
SMC contraction, and a gain of function, leading to increased SMC proliferation (Figure 
VI-1).   
 
Figure VI-1. A model for disease pathogenesis due to loss of SM α-actin filaments.  
************************************************************************** 
Loss of Contractile Function Resulting From MYH11 and ACTA2 Mutations. 
 Multiple lines of evidence support a loss of contractile function in ACTA2/MYH11 
aortas. All of the currently identified mutations in MYH11 and ACTA2 are predicted to 
disrupt the structure and/or function of the protein. Mutations in MYH11 located in the 
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ATPase domain are predicted to impair ATPase activity, and mutations in the coiled-coil 
domain are predicted to disrupt the structure (36). Mutations in ACTA2 are predicted to 
adversely affect actin polymerization and interaction with other proteins (34). Patients with 
MYH11 mutations showed a decrease in aortic compliance (86). Mice deficient in either 
Acta2 or Myh11 have decreased contractility of arterial segments, supporting that loss of 
either of these contractile protein leads to decreased SMC contractility. Our data show that 
SMCs explanted from both patients with ACTA2 and MYH11 mutations failed to form SM 
α-actin filaments, the thin filaments required for contractile function. Loss of SM α-actin 
results in decreased aortic contractility in the Acta2-/- mouse, demonstrating that SM α-actin 
is required for maximal force generation by SMCs (117). Therefore, the disruption in 
contractile filament structure is highly likely to result in decreased contractile function. 
 In addition to the histologic data in patients’ SMCs and myofibroblasts, our study of 
FAs in Acta2-/- mouse SMCs also support the notion that the decreased contractility due to 
loss of SM α-actin filaments disrupts FAs and actin filament associated proteins in SMCs. 
Immunofluorescent labeling of vinculin, a marker for FAs, showed a marked reduction in 
FAs, with the remaining FAs located mainly at the cell periphery in Acta2-/- SMCs. The 
amount of vinculin localized in FAs correlates with the amount of contractile force being 
generated across FAs by SMCs, and vinculin localization to FAs is necessary in order to 
transmit this contractile force (207). Therefore, the disruption in vinculin likely indicates a 
loss of contractile function in the Acta2-/- SMCs. Actin thin filaments are anchored to the 
cell at integrin-containing FAs in SMCs (60). Since integrin signaling at FAs allows for 
communication with the ECM and transduction of mechanical force between the cell and the 
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ECM, a disruption in one component of this mechanism is likely to disrupt the development 
of mechanical force by the SMC (178).  
 Data from these studies strengthen a growing body of evidence that one of the 
primary underlying defects in TAAD pathogenesis is the disruption of the structure and/or 
function of the SMC contractile unit (12). This disruption leads to an impairment of cell-
matrix communication, and secondarily may lead to secretion of cytokines and growth 
factors, as well as release of latent factors from the ECM. Interestingly, a similar 
pathogenesis has been suggested for mutations in cardiac contractile protein mutations that 
lead to hypertrophic cardiomyopathy (96). Our data showing the upregulation of IGF-1 
transcript levels in patients with ACTA2 and MYH11 mutations suggest that the SMCs are 
compensating for a loss of contractile function by increasing production of this particular 
growth factor, which is known to drive the expression of contractile proteins in SMCs   
 Additional studies from our lab and from others support this hypothesis. Other 
factors that lead to increased pressures on aortic SMC contractile units, such as hypertension 
or heavy weightlifting, lead to ascending aortic aneurysm formation. This overload of SMCs 
may induce activation of SMC pathways in a similar manner to pathways induced due to 
defects in SMC contraction due to mutations in contractile proteins.  In addition, other 
mutant genes identified to predispose to thoracic aortic disease may also lead to decreased 
contractile function of SMCs. Experimental evidence suggests that SMCs from TGFBR2 
mutant individuals fail to maintain a differentiated, contractile phenotype (Inamoto et al., 
manuscript submitted). Mutations in MLCK disrupt kinase activity of the enzyme, 
suggesting disruption in SMC contractility (Wang et al., manuscript submitted). Even in 
cases of FBN1 mutations, where TGF-β1 has been shown to play a role in disease 
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pathogenesis, the mutations are also likely to disrupt contractile function. As mentioned 
previously, fibrillin-1 binds to αvβ3, α5β1, and αvβ6 integrins on the surface of SMCs, and 
fibrillin-1 containing microfibrils form an essential part of the connections between SMCs 
and elastic fibers (11;13). Missense mutations in FBN1 disrupt formation of these 
microfibrils, leading to decreased microfibrils in the vessel wall (12). Therefore, FBN1 
mutations may also perturb the SMC mechanotransduction complex and lead to decreased 
contractility. In mice that underexpress fibrillin-1, one of the early pathologic abnormalites 
noted was a smooth appearance of elastic fibers, suggestive of a loss of connectivity 
between the ECM and SMCs (22). Decreased contractility has also been reported in the 
aortas of MFS mice harboring a heterozygous missense mutation in fibrillin-1, due to loss of 
elastic fibers and increased matrix metalloprotease activity (24). This is consistent with the 
idea that any disruption in the connections between SMC contractile filaments, focal 
adhesions, and the ECM ultimately result in a decrease in contractility.  
 
Gain of Proliferative Function 
 Our data also indicate a gain of proliferative function in smaller arteries, which has 
been a major focus of this work. Histologic and clinical data from patients heterozygous for 
either ACTA2 or MYH11 mutations, as well as data from Acta2-/- mice, suggest that SMC 
hyperproliferation occurs associated with ACTA2 mutations, both in vitro and in vivo. 
Histologic data show focal areas of increased SMCs in the aortic media of ACTA2 and 
MYH11 patients. Additionally, thickening of the medial layer of the arteries in the vasa 
vasorum due to increased SMCs was noted, leading to stenosis or occlusion of these arteries. 
Abnormal thickening of epicardial arteries, and luminal narrowing or a coronary artery due 
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to fibrocellular intimal plaque formation was observed. Clinical data also indicate that 
excessive SMC proliferation may be occurring. Individuals harboring ACTA2 mutations 
have increased likelihood of developing CAD, stroke, or Moyamoya disease, in the absence 
of other cardiovascular risk factors including hypertension, smoking, and 
hypercholesterolemia. An individual heterozygous for a recently identified de novo ACTA2 
mutation, R179C, was found to have aortic coarctation, a narrowing of the aorta resulting 
from hyperproliferation of SMCs (Dianna Milewicz, personal communication) (212). Other 
individuals with the same de novo mutation had primary pulmonary hypertension, which 
was diagnosed based on SMC proliferative lesions in the pulmonary vasculature (Dianna 
Milewicz, personal communication). Data indicating medial thickening in Acta2-/- mouse 
aortas suggest that SMC proliferation is occurring in vivo in these mice due to total loss of 
SM α-actin. Future study will determine whether this proliferation is occurring before or 
during expansion of the vessel wall. In addition, more excessive SMC proliferation leading 
to significant stenoses of arteries was found with arterial injury in the Acta2-/- mouse when 
compared with wildtype mice (Dianna Milewicz, personal communication).   
 SMCs and myofibroblasts expressing SM α-actin from ACTA2 mutant individuals 
displayed a significant increase in proliferation in vitro compared with controls. Complete 
loss of Acta2 leads to increased SMC proliferation as well as migration in vitro, consistent 
with published data from Acta2-/- kidney myofibroblasts (124). Further investigation 
revealed a role for FAs, and specifically a role for excessive activation of FAK signaling, in 
mediating proliferation in Acta2-/- SMCs. Treatment of Acta2-/- SMCs with two different 
FAK inhibitors completely blocked increased proliferation when the cells were plated on 
fibronectin-1, suggesting a role for FAK in Acta2-/- SMC proliferation.  
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Focal Adhesion Dependent Regulation of Proliferation in Acta2-/- SMCs 
 We are proposing a novel vascular disease mechanism in which disruption of a 
SMC-specific contractile protein leads to SMC hyperplasia through altered signaling at focal 
adhesions, and propose this increased proliferation can lead to occlusive vascular lesions. 
SM α-actin stabilizes FAs in myofibroblasts (181). In our model of disease progression, loss 
of SM α-actin filaments would lead to destabilization of FA complexes, resulting in 
localization of FA complexes mainly at the cell periphery. Consistent with this notion, 
vinculin was localized mainly at the cell periphery in Acta2-/- SMCs. We also observed 
increased phosphorylated FAK localization at the cell periphery. Since FAK activation in 
part drives SM α-actin expression in response to external forces on the cell, it is possible that 
increased phosphorylated FAK at the cell periphery is a compensatory response due to loss 
of SM α-actin in the Acta2-/- mice (183). Activated FAK facilitates FA turnover, and also 
leads to activation of multiple cellular pathways capable of driving increased proliferation, 
including ERK, PI3K/Akt, Rho/ROCK, and Rac/JNK (67;68;184;185). Therefore, we 
propose that loss of Acta2 leads to a destabilization of FAs and subsequent increase in FAK 
signaling, and that FAK activates multiple cellular pathways to drive proliferation (Figure 
VI-2). 
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Figure VI-2. Pathways downstream of FAK potentially driving increased proliferation in 
Acta2-/- SMCs compared with wildtype SMCs.  
************************************************************************** 
Inhibitor assays using two different FAK inhibitors reversed the increased proliferation in 
Acta2-/- SMCs to levels similar to wildtype cells, suggesting that Acta2-/- SMCs proliferate 
in a FAK-dependent manner. Further, this FAK-dependent proliferation may be driving 
occlusive vascular lesions in response to injury. Data obtained in our lab show that 
neointimal formation is increased following carotid artery ligation in Acta2-/- mice compared 
with wildtype. Additionally, other models of carotid injury-induced proliferation are 
connected with FA regulation. Balloon injury of rat carotid arteries leads to decreased 
expression of integrin-linked kinase and disruption of FA formation (73). These data are 
consistent with another report that deletion of integrin-linked kinase (ILK), another FA-
associated kinase, disrupts FA maturation (201). Together, these data provide support for a 
novel pathway in which Acta2 deficiency leads to increased proliferation through disruption 
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of FAs and subsequent increases in FAK-dependent signaling. Future work will determine 
which specific pathways downstream of FAK are driving the increased proliferation.  
 
Parallels With NF1 Vasculopathy 
The diffuse vasculopathy found in ACTA2 patients bears similarities to the 
vasculopathy found in patients with Neurofibromatosis type I (NF1), an autosomal dominant 
disorder that results in effects on mainly the nervous system, but also the vascular system as 
well. NF1 has been shown to lead to stenosis or occlusion of arteries, and less commonly, to 
aneurysm formation. Both ACTA2 mutations and NF1 can also lead to occlusive disease in 
multiple vascular beds, and this spectrum of occlusive disease includes aortic coarctation, 
and also Moyamoya disease (213). The human NF1 gene, encoding neurofibromin, 
functions as a negative regulator of Ras signaling in SMCs, suggesting a link between NF1 
mutations and the SMC hyperplasia leading to vessel stenosis and occlusion (214).  
Nf1 deficient mice display increased responsiveness to vascular injury compared to 
their wildtype counterparts. Mice with heterozygous for a deletion in the Nf1 gene display 
increased neointimal formation after vascular injury (72). This proliferation can be inhibited 
both by blocking Ras-mediated signaling and through treatment of the mice with Gleevec, a 
pharmacological inhibitor of Ras (72;215).  The proliferative response to injury in Acta2-/- 
mice parallels the response to carotid injury observed in Nf1 deficient mice. Interestingly, 
neurofibromin, the protein encoded by Nf1, was recently found to interact directly with FAK 
(216). Nf1-/- MEF cells are more elongated, and FAK is redistributed to the cell periphery, 
specifically at the leading edge of the cells (216). Together, these data, along with our data 
from Acta2-/- mice, support the notion that disruptions in a single gene can lead to occlusive 
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disease in multiple vascular beds. Further, these studies implicate SMC proliferation in the 
formation of these occlusive diseases and further support our hypothesis that disruptions in 
FAs lead to a proliferative vascular response to injury.   
 
Future Research Directions 
 Future work will focus both on mouse models of ACTA2 and MYH11 mutations and 
confirmation of results in human tissue and cell samples. Plans for the immediate future 
include further characterization of the Acta2-/- mouse model, as well as development of 
transgenic and knock-in mice that carry the R258C mutation, one of the more severe 
mutations in ACTA2.  Mice will be imaged using MRA, as well as echocardiography, to 
confirm aneurysm formation and determine the earliest age of onset of disease. Pathological 
study of these mice should provide further insight into the major mechanisms driving 
aneurysm formation due to SMC contractile mutations.  Mouse models will aid in 
elucidating the specific role of FAs and FAK in increased proliferation leading to the 
occlusive lesions in vivo. Acta2-/- mice display increased neointimal formation post carotid 
artery ligation: future work will determine 1) whether this holds true in transgenic and 
knock-in mouse models and 2) whether this increase can be blocked through treatment of 
mice with a FAK inhibitor.  
 The mouse models will also aid in determining whether increased proliferation plays 
a role in aneurysm formation, and whether this proliferation is FAK-dependent. Some 
experimental evidence exists to suggest a role for increased cell proliferation in aneurysm 
formation. The observation of focal areas of increased SMCs in ACTA2 and MYH11 aortic 
tissues supports this idea. Also, LDLR-related protein (LRP) deficient mice develop 
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aneurysms with medial thickening, atherosclerosis, and SMC hyperplasia (217). Another 
group reported medial thickening and sustained SMC density in TAA, implying that SMCs 
proliferated to maintain the same density as the aortic wall expanded (82). It is interesting to 
note that aneurysm formation is evident in Acta2-/- mice with only minimal changes typical 
of medial degeneration (increased proteoglycans and elastic fiber degradation).  The only 
pathologic abnormality noted is increased SMCs in the aortic medial layer.  This observation 
raises the possibility that excessive SMC proliferation may contribute to aneurysm 
formation.  Furthermore, we are interested in determining if blocking this proliferation will 
prevent aneurysm formation.  Once a role for FAK inhibitors in preventing neointimal 
proliferation in response to carotid ligation has been established, mice will be treated with 
FAK inhibitors prior to the onset of TAA formation. MRA and histologic studies will be 
used to determine whether FAK inhibition prevents aneurysm formation and associated 
medial degeneration.  
 Further work is needed to better quantify and characterize the specific alterations in 
FAs in Acta2-/- mice as well as in human samples. Our studies of Acta2-/- mice showed 
alterations in vinculin as well as zyxin. Total internal reflection fluorescence (TIRF) 
microscopy will be used to quantify the amounts of these and other FA proteins, including 
FAK and tensin, localized specifically on the cell membrane. Additionally, the results 
showing alterations in zyxin localization require follow-up to 1) confirm the results are bona 
fide and 2) determine the specific subcellular structure(s) that zyxin is localized to in the 
Acta2-/- SMCs.  
 We also plan to determine whether FAs are altered in human myofibroblast and 
SMC samples from TAAD patients. Initial study will focus on samples harboring ACTA2 or 
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MYH11 mutations, and will later be expanded to determine whether alterations in FAs are 
commonly disrupted in TAAD. There is a possibility that other TAAD mutations lead to a 
common disruption of FA formation and/or maturation. Data from our lab showing that 
MYLK mutations disrupt myosin light chain kinase function in SMCs, together with another 
study showing that myosin light chain kinase inhibitors prevent FA maturation, support this 
idea (Wang et al., manuscript submitted) (218).  
 Another issue to pursue using the mouse models is the question of whether TGF-β1 
signaling contributes to the pathogenesis of aneurysms caused by contractile mutations. 
While our initial data from human subjects does not indicate that increased TGF-β1 
signaling is present, we currently cannot completely rule out the possibility of TGF-β1 
involvement in pathogenesis. We have proposed that the major underlying defect in these 
patients, and the initial insult that leads to disease progression, is the defective ability of 
SMCs to contract properly, resulting in alterations in focal adhesion maturation and/or 
stability. However, TGF-β1 may still play a role in disease pathogenesis. Treatments that 
have been utilized in preventing aneurysm formation in mouse models of MFS such as TGF-
β1 neutralizing antibodies, Doxycycline, or Losartan should provide insight into 1) whether 
TGF-β1 is contributing to pathogenesis in the Acta2-/- and transgenic and knock-in mouse 
models, and 2) whether similar treatments under development for treating MFS would also 
be beneficial for treating familial TAAD patients, particularly those with mutations in 
MYH11/ACTA2.  
 Since we observed increases in IGF-1 in ACTA2 and MYH11 patients, it is 
particularly interesting to note that the IGF-1 receptor and FAK interact in SMCs as well as 
other cell types. The IGF-1 receptor stimulates FAK phosphorylation in SMCs (219). 
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Conversely, FAK activates the IGF-1 receptor independently of IGF-1R 
autophosphorylation and also stabilizes the expression of the receptor (220). In human 
pancreatic adenocarcinoma cells, multiple combinations of FAK and IGF-1R inhibitors 
synergistically blocked cell proliferation, whereas proliferation was not inhibited with use of 
either FAK inhibitors or IGF-1R inhibitors alone (221). In our studies, an IGF-1R inhibitor 
failed to prevent increased proliferation in ACTA2 mutant myofibroblasts. It is possible that 
either a FAK inhibitor alone, or dual inhibition using lower doses of both FAK and IGF-1R 
inhibitors may completely prevent ACTA2 mutant myofibroblast proliferation.   
 In conclusion, the data gained from this study provide support for the existence of a 
hyperplastic vasculomyopathy leading to diffuse and diverse vascular diseases in the 
absence of other cardiovascular risk factors including hyperlipidemia, smoking, and 
hypertension. Further, the ideas of 1) FAK dependent mechanism of SMC hyperproliferation 
and 2) a role for SMC proliferation in aneurysm formation suggest that FAK inhibition may 
be a viable treatment option in the future for TAAD associated with early-onset vascular 
occlusive diseases.  
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